Skip to main content
Erschienen in: Journal of Translational Medicine 1/2023

Open Access 01.12.2023 | Review

The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies

verfasst von: Zijing Tang, Shiyan Yu, Yu Pan

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2023

Abstract

Chronic kidney disease (CKD) affects more than 10% population worldwide and becomes a huge burden to the world. Recent studies have revealed multifold interactions between CKD and gut microbiome and their pathophysiological implications. The gut microbiome disturbed by CKD results in the imbalanced composition and quantity of gut microbiota and subsequent changes in its metabolites and functions. Studies have shown that both the dysbiotic gut microbiota and its metabolites have negative impacts on the immune system and aggravate diseases in different ways. Herein, we give an overview of the currently known mechanisms of CKD progression and the alterations of the immune system. Particularly, we summarize the effects of uremic toxins on the immune system and review the roles of gut microbiota in promoting the development of different kidney diseases. Finally, we discuss the current sequencing technologies and novel therapies targeting the gut microbiome.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Chronic kidney disease (CKD) is one of the most important chronic diseases worldwide, affecting the well-being of many people. Currently, the main therapies for CKD are renin–angiotensin aldosterone system inhibitors with drugs for symptomatic treatment and dietary restriction. However, these interventions have achieved limited benefits. Recently, an increasing body of data has implicated that both the progression of CKD and its complications are related to the disturbed gut microbiome in patients with CKD.
Gut microbiome is considered a “living organism” that coevolves with the host. Compared with the human body, it exceeds the number of cells in the human body by a factor of 10 [1]. The gut microbial genes are 100-fold greater than human genes, indicating the diversity of microbial species [2]. In healthy individuals, microbial communities as well as their metabolites perform multiple beneficial functions through bacterial-host and bacterial-bacterial interactions. The flora composition can be altered by many environmental factors such as dietary habits, drugs and disease conditions [3]. The kidney diseases, such as IgA nephropathy (IgAN), diabetic nephropathy (DN) and end-stage renal disease (ESRD) with hemodialysis (HD) or peritoneal dialysis (PD), can discompose intestinal microbial ecologies, referred to as dysbiosis [4]. Extensive efforts have been invested toward unveiling the changes. For example, Vaziri et al. discovered that 175 operational taxonomic units (OTUs) were different between CKD and healthy rats, and the richness of OTUs was decreased in CKD group [5]. At the family level, both Lactobacillaceae and Prevotellaceae were notably reduced, resulting in a decreased production of short chain fatty acids (SCFAs). This is attributed to the enrichment of phosphotransbutyrylase and butyrate kinase in these two taxa. Whereas the urease- and uricase-containing and indole- and p-cresol-forming intestinal microbiota increased, such as Enterobacteriaceae, Pseudomonadaceae, and Clostridiaceae [5, 6]. In return, gut dysbiosis is also involved in the onset and progression of CKD and complications. The potential mechanisms are associated with immune dysfunction, translocation of bacteria via impaired intestinal barriers and increased production of gut-derived uremic toxins [7, 8]. Among them, the protein-bound uremic toxins (PBUTs), such as indoxyl sulfate (IS), p-cresol sulfate (pCS) and indole-3-acetic acid (IAA), are defined as potential immune-modulatory candidates. These metabolites cause the dysfunction of immune cells and induce the production of pro-inflammatory cytokines and chemokines. The permeability of the gut barrier increases in CKD, leading to the translocation of inflammatory factors and uremic toxins into circulation. This contributes to vascular damage, glomerular sclerosis, kidney fibrosis and tubular damage, promoting inflammation and resulting in adverse outcomes and complications of CKD, such as cardiovascular disease (CVD) [911]. Thus, the pathological interactions between kidney disease and dysbiosis could generate vicious cycles accelerating kidney disease progression (Fig. 1).
Recent years witness the emergence of new methods, such as next-generation sequencing (NGS) and third-generation sequencing (TGS). In addition, researchers prefer to integrate multi-omics analysis to unravel the intricate interactions between the gut microbiome and CKD. These methods have improved our understanding of the gut flora ecosystem, which fuels the search for novel diagnostic methods and treatments for CKD.
In this review, we will focus on the effects of the gut microbiome on CKD progression and immune dysfunction. Additionally, advanced detection techniques and potential therapeutic avenues for CKD will also be discussed.

Mechanisms of CKD progression

CKD is a common chronic disease with a high rate of morbidity and mortality, affecting approximately 843.6 million population worldwide [12]. Kidney Disease: Improving Global Outcomes (KDIGO) defines CKD as abnormalities of kidney structure or function, present for > 3 months, with implications for health [13]. Based on the glomerular filtration rate (GFR), CKD is classified into 5 categories. From 2017 to March 2020, the prevalence of CKD stages 1–4 was 14.7%, and the crude incidence rate of CKD stage 5, namely ESRD, will increase 11–18% from 2015 to 2030, which is a huge medical burden for the whole world [14, 15].
The mechanisms of CKD progression are enormously complex and only partly understood. Several factors have been implicated in contributing to the pathophysiological and pathological alterations observed in individuals with CKD, including but not limited to hyperglycemia, hypertension, infections, high-protein diets, and others. From a pathophysiological point of view, hyperglycemia, hypertension and immune dysfunction can directly cause cellular damage. In response to these insults, the reactive oxygen species (ROS), pro-inflammatory and pro-fibrosis factors increase in circulation, and the immune complexes deposit in the glomerulus. This leads to damage to the glomerulus and decreased GFR. The declined GFR activates the renin-angiotensin system (RAS), shown by the increasing levels of angiotensin-II to elevate the glomerular hydrostatic pressure and filtration, ultimately compromising the glomerular barrier [16]. Apart from controlling vascular pressure, angiotensin-II also induces factors that regulate inflammation and fibrosis [16]. These pathophysiological changes further result in glomerular sclerosis, tubulointerstitial fibrosis, and proliferation of mesangial cells. The pathological remodeling of kidney infrastructure is closely associated with clinical manifestations such as albuminuria and hematuria. Furthermore, uremic toxins are retained and actively participate in the processes of CKD progression stated above. The resulting disturbances in the humoral environment can impair other systems, causing CVD, bone diseases, abnormal immunity, etc. [17].
The immune dysfunction of CKD has been well reviewed elsewhere [18]. These immune abnormalities can further exert negative effects on patients with CKD. Toll-like receptor (TLR) 2 and TLR4 play a significant role in the inflammation pathway [19]. Patients with CKD exhibit the upregulation of Toll-like receptor (TLR) 2 and TLR4 on neutrophils and monocytes partly due to the elevated production of pro-inflammatory cytokines and ROS [20]. These inflammatory factors can also cause tissue impairment and are related to low GFR [21]. There is an increase in the number of peripheral polymorphonuclear leukocytes (PMNLs) in patients with CKD, which is demonstrated to be negatively correlated with GFR [22]. Besides, the proportion of CD14+CD16+ monocytes and CD4+CD28 T cells increases [23, 24]. Both subtypes exhibit notable proinflammation ability and are related to CVD in patients with ESRD [25, 26]. Moreover, the anti-bactericidal activity of neutrophils decreased, leading to increased susceptibility to infection. For instance, the ability of neutrophils to generate extracellular NET formation (NETosis) is severely impaired, favoring the invasion of pathogens [27]. In addition to causing complications, immune dysfunction also contributes to poor vaccine response in patients with ESRD [28]. It may be related to the decreased stimulation ability of dendritic cells (DCs) and impaired antigen-specific T cell differentiation [29].

Effects of gut-derived metabolites on CKD

Uremic toxins can be divided into three categories: small water-soluble, protein-bound and middle molecules. Among them, several metabolites, such as IS, pCS and IAA, are in the limelight. All three are PBUTs. Unfortunately, they can hardly be removed by dialysis, because the molecule size of PBUTs exceeds the upper limit of dialysis membranes [30]. Moreover, HD cannot replace tubular secretion, which is the main mechanism of PBUTs excretion. Similar to HD, PD cannot compensate for the reduced renal function, and the restriction coefficient of its membrane for macromolecules increases over time [31]. PD even has a lower clearance of PBUTs than HD [32]. Besides, studies showed that hemodiafiltration (HDF) has no notable effects on removing PBUTs in the long term, even though its efficacy is higher than HD [33, 34]. Therefore, PBUTs accumulate in patients with CKD as the kidney function decreases, especially in advanced CKD stages.
Moreover, aside from toxins, gut microbiota can also produce metabolites with renoprotective properties such as SCFAs. The impacts of PBUTs and renoprotective metabolites are outlined in Table 1.
Table 1
Effects of gut-derived metabolites on kidney diseases
Protein-bound Uremic toxins
Effects
Refs.
Indoxyl sulfate
Increase of IL-1β and TNF-α in human monocytes
[37]
 
Induction of TNF-α in macrophages
[39]
 
Elicit adhesion and extravasation of leukocytes in mice
[41]
Indole-3-acetic acid
Damage of DNA and ultrastructural in neutrophils
[43, 44]
 
Resulting in death of neutrophils
p-Cresol sulfate
Increase of the percentage of free radical-producing leucocytes
[47]
 
Inhibition of the production of IFN-γ in mouse T cells
[49]
 
Inhibition of IL-12 in macrophages
[50]
 
Suppression of the proliferation of CD43+ B-cell progenitors
[51]
Reno-protective metabolites
Effects
Refs.
Butyrate
Decrease of urine BUN and Scr levels; attenuation of renal pathology; reduction of macrophage infiltration and kidney inflammation
[60]
 
Improvement of intestinal barrier and insulin sensitivity
[61]
Acetate
Retard of inflammation by inhibiting histone acetylation (HDAC) activity of T cells
[62]
Propionate
Alleviation of the increased Scr and BUN via the fatty acid receptor 2 (FFA2) or FFA3 pathway
[63]
 
Inhibition of inflammation in HD patients
[64]

Effects of PBUTs on immune cells

These accumulated toxins have multiple biological effects, of which the harmful effects on immune cells have gained more interest.

Indoxyl sulfate

Indoxyl sulfate (IS) is metabolized from tryptophan. Tryptophan first is metabolized into indole by gut bacteria such as Escherichia coli, Proteus vulgaris, Paracolobactrum coliforme, Achromobacter liquefaciens, and Micrococcus aerogenes and then is hydroxylated and sulfated to circulating IS in liver [35].
The effects of IS on immune cells have been shown to contribute to kidney and vascular damage in patients with CKD. The tryptophan derivates are the ligands of aryl hydrocarbon receptor (AhR), which is expressed on kinds of immune cells and provides immune function [36]. Through the AhR pathway, IS induces human monocytes to produce interleukin (IL)-1β and tumor necrosis factor-α (TNF-α). IL-1β is involved in the onset and progression of tubulointerstitial fibrosis [37]. The increasing level of TNF-α can elicit the production of CX3CL1 in vascular endothelial cells, which will recruit CD4+CD28 T cells that express CX3CR1. The activated CD4+CD28 T cells cause endothelial cells to undergo apoptosis [38]. In macrophages, IS induces TNF-α production involving crosstalk among the AhR, NF-kB, and the suppressor of cytokine signaling (SOCS)2 [39]. In addition, IL-6, one of the pro-inflammatory factors, is proven to be notably related to the free IS level [40]. IS also induces adhesion and extravasation of leukocytes in a murine experiment, causing vascular impairment [41].

Indole-3-acetic acid

Indole-3-acetic acid (IAA) also originates from tryptophan and belongs to the family of indole, which is metabolized by bacterial tryptophan monooxygenases and indole-3-acetamide hydrolases [42]. As a tryptophan derivate, IAA can also activate AhR. In addition, IAA has multiple effects on neutrophils, which may contribute to the development of infection. The production of \({\text{O}}_{2}^{-}\) and H2O2 activated by IAA leads to death and significant ultrastructural changes in cultured neutrophils [43]. IAA damages the DNA of neutrophils in a dose-dependent manner, resulting in the death of neutrophils [44]. Similar to IS, IAA can impair the vascular. In cultured human endothelial cells, IAA upregulates the expression and activity of COX-2 by activating an AhR/p38 MAPK/NF-κB signaling pathway and increases ROS production in endothelial cells, which induces endothelial inflammation and oxidative stress [45]. A study has demonstrated that serum IAA has predictive value for mortality and cardiovascular events in CKD [45].

p-Cresol sulfate

p-Cresol is the product of tyrosine, most of which is sulfated to p-Cresol sulfate (pCS) in colon [46].
pCS exhibits both pro-inflammatory and immunosuppressive effects at different stages of CKD, which involves the progression of CKD and its complications. Schepers et al. showed the pro-inflammatory effect of pCS for the first time, which functions by increasing the percentage of free radical-producing leucocytes [47]. Similarly, Azevedo et al. described the elevated ability of NO production and phagocytosis in macrophages in the early stage of CKD. However, in advanced stages, the high concentration of pCS could cause immunosuppression [48]. Studies showed that pCS could inhibit the production of IFN-γ by decreasing Th1 cells and the production of IL-12 in macrophages, thus suppressing immune responses [49, 50]. In adenine-induced renal dysfunction mice, pCS could suppress the phosphorylation of STAT5, which is a vital process in the proliferation and survival of CD43+ B-cell progenitors. Therefore, pCS inhibited the proliferation of CD43+ B-cell progenitors [51]. The resulting reduction of B cells is associated with a decreased response to T-cell-independent vaccines in patients with ESRD [52]. The immunosuppression mechanisms may contribute to infection including septicemia, which is one of the leading causes of death in ESRD patients.
In addition to the reduced clearance, increased protein fermentation of gut flora also contributes to the elevated level of PBUTs. In CKD patients, the colon transit times are prolonged [53]. Moreover, the protein digestion of the upper gut is impaired, leading to the protein increase in colon [53]. A recent study linked gut flora in patients with CKD to uremic toxins levels. In this study, the abundance of Escherichia_Shigella is positively correlated with serum levels of IS; Alistipes is positively associated with total levels of IS and pCS [54].

Effects of PBUTs on CKD progression

PBUTs are involved in fibrosis and inflammation in CKD. A recent study revealed that IS induces epithelial-to-mesenchymal transition (EMT) in human proximal tubular cells (HK-2), providing a potential mechanistic link to renal fibrosis [55]. Poveda et al. have reported that pCS causes cell death in HK-2 cells. The findings also showed that pCS increases expression of the TWEAK receptor Fn14 and cooperates with inflammatory cytokine TWEAK, collectively contributing to kidney damage [56]. Watanabe et al. explored the effects of pCS on renal tubular cells. They found that pCS led to the elevation of Nox4 and p22phox expression, resulting in the increase of ROS production through Nox4 and p22phox NADPH oxidase. Thereafter, ROS mediates the increase of pro-inflammatory and pro-fibrotic factors, ultimately contributing to damage in tubular cells [11]. PBUTs have been found to elicit comparable deleterious effects on cellular function. IS and pCS have been shown to inhibit the expression of Klotho in renal tubules of mice by DNA methylation, contributing to renal tubule senescence [57]. Moreover, both IS and pCS can elicit an increase in Tgfb1 expression in proximal renal tubular cells, which is related to immunomodulation and fibrosis [58]. The activation of RAAS is widely acknowledged as a critical mechanism driving the progression of CKD [16]. Both IS and pCS have been demonstrated to increase levels of renin, angiotensinogen and the expression of AT1 receptor, contributing to kidney injury [10]. Furthermore, it has been observed that uremic toxins can also affect metabolism in human renal proximal tubule cells. A study has revealed the involvement of both IAA and IS in reducing the activity of the mitochondrial electron transport chain, leading to decreased NAD + levels and subsequent attenuation of UDP-glucuronosyltransferases (UGT)-mediated metabolism [59].

Reno-protective metabolites

In healthy individuals, gut microbiota ferments carbohydrates into SCFAs e.g., acetate, propionate and butyrate. Unfortunately, these microbiota-producing SCFAs are decreased in CKD. Notably, SCFAs have been attributed with a protective role in CKD, exerting anti-inflammatory effects, enhancement of gut barrier integrity, and amelioration of insulin sensitivity. Li et al. found that butyrate improves renal fibrosis, renal lesion and tubular injury through the GPR43 pathway. Moreover, it inhibits lipopolysaccharide-induced overexpression of proinflammatory Il1b and Il6 in both kidney tubular epithelium cell and renal podocyte. The researchers observed reduced infiltration of macrophage in the kidney upon butyrate treatment [60]. In addition, Gonzalez et al. demonstrated the improvement of 5ʹ adenosine monophosphate-activated protein kinase (AMPK) phosphorylation by butyrate, resulting in enhanced gut barrier and reduced leakage of gut-derived uremic toxins. Butyrate mediates the secretion of glucagon-like peptide-1 (GPL-1), ameliorating insulin sensitivity [61]. Furthermore, acetate mitigates the inflammation in CKD by inhibiting the histone acetylation (HDAC) activity of T cells, correcting the oxidant-antioxidant imbalance in T cell [62]. As for propionate, researchers found that it alleviates the increased serum Cr (Scr) and BUN as well as inflammation via the GPR43 or GPR41 pathway [63, 64].

Roles of the microbiome in CKD

The impacts of the gut microbiome on CKD

IgA nephropathy

IgA nephropathy (IgAN) is the most prevalent disease among primary glomerulonephritis with 25 cases per 100,000 persons worldwide [65]. The pathogenesis of IgAN has been described as a multi-hit mechanism, the most important of which is the synthesis of galactose-deficient IgA1 (Gd-IgA1) [66]. Evidence has emerged suggesting the involvement of the gut microbiome in this pathogenetic process. Several studies have shown a reduction in cell densities and diversity of intestinal microbiota in IgAN patients when compared to healthy individuals [67, 68]. Additionally, research has indicated that Sutterellaceae and Enterobacteriaceae increase, both of which are LPS-producing bacteria [68]. In addition to inducing systemic inflammation, LPS significantly inhibits the expression of core I β3-Gal-T-specific molecular chaperone (Cosmc) mRNA and leads to methylation of the Cosmc by activating toll-like receptor 4 (TLR4) [69]. Cosmc is a critical molecular chaperone of IgA1 glycosylation [70]. Therefore, the decrease of Cosmc can cause the increase of circulating Gd-IgA1. The accumulated Gd-IgA1 can stimulate B cells to produce IgG, resulting in the sequential deposition of IgG-Gd-IgA1 immune complexes in kidney [71]. The complexes induce mesangial cell proliferation and the production of extracellular matrix components [66]. Moreover, in BAFF-overexpressing transgenic mice (BAFF-Tg mice), the presence of commensal microbiota is indispensable for IgA production and collaborates with high levels of BAFF to participate in the pathogenesis of IgAN [72]. Besides, the uremic toxins produced by imbalanced gut flora induce the release of pro-inflammatory cytokines and cause subsequent systemic inflammation, further contributing to the progression of IgAN [73].
Furthermore, a recent investigation has elucidated the correlation between intestinal microbiota and clinical manifestation of IgAN, shown by increased Escherichia-Shigella and reduced Bifidobacterium in patients with severe haematuria and proteinuria [74]. In another study, antibiotic administration leads to decreased formation of glomerular deposition and prevents proteinuria in a humanized mouse model of IgAN [75]. Therefore, targeting the gut microbiome may be a promising strategy to prevent the initiation and progression of IgAN.

Diabetic nephropathy

Approximately 40% of patients with diabetes that is poorly controlled develop diabetic nephropathy (DN), which has been the leading cause of CKD over the past years [76, 77]. DN is characterized by decreased glomerular filtration rate and increased albuminuria and seriously affects patients’ quality of life.
Current views hold that the activated RAS plays a pivotal role in renal dysfunction of DN [78]. The release of renin and Ang II can cause extracellular matrix accumulation and injury of renal cells [79]. The important metabolites of gut microbiota, SCFAs, are reported to participate in RAS regulation [80]. Acetate can activate olfactory receptor 78 (Olfr78) that is expressed on renal juxtaglomerular afferent arteriole, leading to the release of renin and subsequent increase in blood pressure [81]. In addition, acetate activates G protein-coupled receptor 43 (GPR43) to cause a disorder of cholesterol homeostasis, contributing to the lipid accumulation in the tubulointerstitium of DN patients [82]. The activation of GPR43 also mediates insulin resistance and thereby causes impairment in podocyte [83]. Podocyte injury is one of the vital mechanisms of albuminuria [84]. Moreover, insulin resistance (IR) also contributes to the progression of DN. IR leads to high insulin levels, which activates the production of plasminogen activator inhibitor 1 (PAI-1), thereby causing mesangial matrix expansion and fibrosis in kidney [85]. Administration of Bifidobacteria and Lactobacillus is observed to improve insulin resistance in type 2 diabetes mellitus (T2DM) [86].
Besides, hyperglycemia can impair the gut barrier, resulting in the increased translocation of gut microbiota and its products [87]. The increases of these metabolites in circulation exert negative effects on patients. For example, the upregulation of pro-inflammatory cytokines and inflammation can be caused by elevated LPS levels [88]. Moreover, LPS is associated with the occurrence of IR [88]. A recent study observed the translocation of gut microbiota and demonstrated its damage to kidney in mitochondrial antiviral signaling protein (MAVS) knockout diabetic mice [89]. MAVS is important in protecting the gut barrier [90]. Furthermore, phenyl sulfate (PS) is one of the gut microbiota-derived PBUTs, which increases in circulation of patients with DN [91]. Koichi et al. demonstrated that PS exerts multiple negative effects, including podocyte injury, mitochondrial dysfunction of the podocyte, and fibrosis in kidney [91]. This study also suggests that PS levels may serve as a predictive biomarker for the progression of albuminuria for incipient patients with DN [91]. In addition to kidney injury, PBUTs also contribute to the complication of DN. IS induces the proliferation of vascular smooth muscle cells, indicating its role in the development of CVD in patients with DN [92].

Acute kidney injury to CKD transition

Acute kidney injury (AKI) is defined as the sudden declination of renal function within a few hours or days. The maladaptive repair in AKI can predispose individuals to progress toward CKD, particularly in the context of kidney aging. Previous studies suggest that gut dysbiosis in AKI accelerates the transition from AKI to CKD. In vitro experiment, Chen et al. demonstrated that IS is associated with hypoxia–reperfusion (H/R) induced G2/M cell cycle arrest, EMT and endoplasmic reticulum stress induction, which may lead to the maladaptive repair of AKI [93]. The cells that are arrested in the G2/M phase may secret pro-inflammatory factors, leading to microvascular rarefaction and collagen disposition in kidney [94]. Moreover, AKI is characterized by severe proximal tubule injury, including the downregulation of organic anion transporter (OAT)-1 and OAT-3, subsequently causing the decreased excretion of uremic toxins such as IS. In addition, the impaired gut barrier caused by both AKI and dysbiosis can indirectly expedite the transition from AKI to CKD. Butyrate is able to activate hypoxia-inducible factor (HIF) -1α in intestinal epithelial cells (IECs). HIF-1α promotes mucin expression and secretion, therefore maintaining the stability of gut barrier [95]. However, the SCFAs are reduced due to gut dysbiosis in CKD, compromising gut barrier and causing the leakage of gut-derived uremic toxins. Yang et al. demonstrated that AKI-induced dysbiosis can contribute to the progression of AKI. The results showed that dysbiosis is associated with increased colonocyte apoptosis, inflammation, and altered tight junction proteins, which may lead to the translocation of endotoxins and further potentiate the inflammation in AKI [96, 97].

Hemodialysis/Peritoneal dialysis

ESRD patients require renal replacement treatment (RRT), such as hemodialysis (HD) and peritoneal dialysis (PD). HD and PD retard the progression of ESRD through clearance of the retention water and removal of some uremic toxins, consequently maintaining the balance of the internal environment.
Infection is an important complication, both in HD and PD. Studies suggest that the gut microbiota may be a source of infectious pathogens. For example, Pseudomonas aeruginosa and Enterobacteriaceae increase in PD patients [98, 99]. P. aeruginosa has been found to be associated with around 40% of catheter removals attributed to infections, while Enterobacteriaceae is responsible for 12.0% of peritonitis cases in PD patients [100, 101]. Moreover, the DNA of P. aeruginosa was found in blood from different vascular access of HD patients [102].
During dialysis, the intestinal barrier is compromised. Increased intraperitoneal pressure in PD contributes to intestinal hypoperfusion [103]. Similarly, HD is always accompanied by reduced hepato-splanchnic perfusion, which leads to intestinal ischemia [104]. Therefore, the subsequent migration of bacteria and its metabolites exerts negative effects on HD and PD patients. For instance, circulating IS and pCS are elevated in HD and PD patients. The harmful effects of IS and pCS on the human body have been reviewed elsewhere, such as endothelial damage, EMT and inflammation [105]. Based on these mechanisms, researchers find evidence that pCS is associated with the morbidity of CVD and all-cause mortality in HD patients [106]. Moreover, pCS and IS can predict the progression of CKD [107].
In addition, constipation is common in dialysis patients. The decrease of commensal bacteria can contribute to the occurrence of constipation. Lactobacillus and Bifidobacterium are associated with faster colonic transit [108]. However, they decreased in PD patients, which may confer negative effects on gut healthy [109]. The mechanisms of intestinal microbiome progress the disease is enormously complex and only partly understood. We need more research to unravel the mysteries.

Microbiota in CKD

The gut microbiome is different in healthy individuals and patients with CKD. Research has revealed an elevated presence of both aerobic and anaerobic microorganisms in the duodenum and jejunum of CKD patients compared to healthy individuals [110, 111]. Moreover, many results demonstrate a notable reduction in the diversity of gut microbiota among CKD patients [5, 112]. Furthermore, a recent study conducted in China enrolled 489 fecal samples to find the alterations in the gut microbiota of patients with CKD compared to healthy individuals [113]. As CKD progressed, researchers observed significant increases in the abundance of genera Thalassospira, Akkermansia, and Blautia, while the genus RF9_norank exhibited a decrease. Particularly, Akkermansia is positively correlated with BUN and Scr, indicating its potential as a valuable diagnostic or therapeutic target in CKD. Moreover, the microbiota involved in the metabolism of ascorbate and aromatic amino acids is enriched in CKD, which aligns with the observed increase in uremic toxins in CKD patients [113].
In addition to the gut, the composition of microbiota in blood holds significant importance. Blood is traditionally supposed to be sterile, however, a recent study challenged this view, providing evidence supporting the existence of blood microbiome in healthy individuals [114]. Shah et al. compared the blood microbiome of patients with CKD and healthy controls. The results showed that the α diversity is decreased in the CKD group, similar to the change in the gut microbiota of CKD. Moreover, Proteobacteria is enriched in the CKD group. This bacteria phylum increased in blood and gut in many chronic diseases. Therefore, decreased diversity of blood microbiota and enriched Proteobacteria in the blood may be the factors contributing to CKD progression [115]. Merino-Ribas et al. explored the blood microbiome in PD patients with or without vascular calcification. They found an increase in Devosia in the blood of PD patients with vascular calcification. Vascular calcification is associated with high mortality risk in PD patients, suggesting that Devosia may be a biomarker or involved in the disease progression [116]. However, many questions remain to be addressed. The precise origin of blood microbiota has yet to be definitively determined. The leaky gut barrier and translocation of microbiota in oral and skin may be the sources [117]. Moreover, liver clearance and the immune system have important effects on the blood microbiome, emphasizing the necessity of incorporating these factors in future investigations [118].
The research on urine microbiome in patients with CKD is still not fully explored. A study enrolled 77 patients with non-dialysis-dependent CKD in order to understand the characteristic of urine microbiome in stage 3–5 CKD. The findings revealed a reduction in the diversity of the midstream urine microbiome concomitant with the decline in eGFR [119]. The possible mechanism may be the altered secretion of uromodulin, which favors the excretion of bacteria [119]. Since secondary urinary tract infection is common in patients with CKD, more attention should be paid to the urine microbiome.

Gut-kidney-heart axis

Among the complications of CKD, CVD stands as a prominent cause of mortality in CKD patients. The pathogenesis of CVD in CKD is multifactorial, involving several mechanisms, including (1) volume overload; (2) overactivation of RAAS; (3) inflammation and oxidative stress [120]. The detailed interaction between the heart and kidney in CKD has been well reviewed elsewhere [121]. Additionally, the gut microbiome also precipitates the development of CVD, particularly by producing uremic toxins. Thereafter, accumulated gut-derived uremic toxins are transferred to circulation through the impaired gut barrier and compromise the cardiovascular system.
The gut-derived uremic toxins exhibit the capacity to provoke vascular damage and promote the development of atherosclerosis. Gut bacteria metabolize choline, choline-containing compounds, betaine, and l-carnitine into trimethylamine (TMA), which is oxidized by flavin-dependent monooxygenase isoforms 1 and 3 (FMO1 and FMO3) to form TMAO in liver [122]. Seldin et al. have elucidated the capacity of TMAO to upregulate the expression of inflammatory genes in endothelial and smooth muscle cells by activating the NF-κB signaling pathway. Moreover, TMAO enhances the endothelial adhesion of leukocytes and contributes to atherosclerosis [123]. In addition, both TMAO and LPS promote atherosclerosis by increasing the expression of osteopontin (OPN) and activating macrophages of aortic [124]. OPN is an independent traditional risk factor of CVD [125]. In addition to TMAO, both IS and IAA possess the ability to increase the expression of TF protein via the AhR pathway, which is associated with several cardiovascular diseases such as atherosclerosis [126]. As reported by Campillo et al., IS and p-cresol can lead to monocytes across the extracellular matrix (ECM) by activating the integrin-linked kinase (ILK) /AKT signaling pathway. The activation of ILK/AKT signaling results in the formation of podosome, which is involved in ECM degradation. The increased degradation of the matrix favors the migration of monocytes and the interaction between migrated monocytes and vascular may cause injury [127].
The vicious cycle among the gut, kidney and heart is intricate, and only a portion of mechanisms is currently elucidated. In addition to metabolites, how gut microbiota itself affects the gut-kidney-heart axis is needed to explore. Nevertheless, targeting this vicious cycle to develop novel interventions holds tremendous potential for yielding significant benefits for patients.

Advances in techniques and methodologies for gut microbiome in CKD research

In the 1970s, scientists detected gut microbiota by culture–based techniques [128]. However, most of the gut flora cannot be cultured in the experimental condition. In the past decades, sequencing technologies and data analysis pipelines develop rapidly and are applied widely, enabling us to put insight into the composition, and capability of the human intestinal microbiome [129]. The pros and cons of technologies have been reviewed elsewhere [130].
With the advance of tools, the understanding of gut microbiome in patients with CKD has been improved a lot. Numerous scholars have reported the composition of gut microbiota by analyzing 16S rRNA sequence data. Compared with healthy control, Klebsiella and Enterobacteriaceae increased, while Blautia and Roseburia decreased in patients with CKD [113]. Further, Wu et al. showed the differences in gut microbiota within different CKD stages. Escherichia_Shigella is significantly enriched in advanced CKD, while Dialiste, Lachnospiraceae_ND3007_group, Pseudobutyrivibrio, Roseburia, Ruminiclostridium spp. decrease with CKD progression [54]. In addition, the comparison between pre-dialysis and dialysis patients is also worthy of attention. A recent study showed that dialysis increases some commensal bacteria and elicits some pathogenic bacteria at the same time compared with non-dialysis ESRD patients [131]. The shotgun approach is sequencing all microbial genomes in the samples. It can provide data with higher resolution than 16S rRNA sequencing and help understand the metabolic activity of microbiota [132]. Recently, Wang et al. explored the taxonomic and function of the microbiome in patients with ESRD utilizing shotgun metagenome sequencing. They found that the amino acid biosynthesis is decreased and amino acid degradation is increased. Moreover, the enzyme involved in aromatic amino acid degradation and secondary bile acid biosynthesis is enriched. This evidence may suggest the source of accumulated uremic toxins in ESRD [133].
Besides, multi-omics analyses combined data from multiple biological sources such as genomics, metagenomics, transcriptomics, proteomics, and metabolomics promote a mechanistic understanding of gut-kidney axis on CKD progression. Opdebeeck et al. found that IS and pCS can induce calcification in aorta and peripheral arteries of rats. The proteomic and bioinformatic analysis identified the proteins in these vessels suggesting that inflammation, coagulation and glucometabolism pathways are correlated with the IS- and pCS-induced calcification [134]. In the metabolomics study, Wu et al. also found that caproic acid is highly positively correlated with eGFR, indicating its role in alleviating the severity of CKD [112]. Using a proteomics approach, Karaduta et al. found that CKD mice exhibited a similar pattern of gut proteins as shown in healthy mice after receiving resistant starch. They further verified the protective role of resistant starch in renal injury [135]. Lobel et al. also applied proteomics to study the relationship between diet, gut and kidney. They identified that TnaA is a highly S-sulfhydrated protein, which is able to catalyze tryptophan to indole. They demonstrated that high sulfated amino acid dietary can inhibit the activity of TnaA by posttranslational modification, reducing the production of the IS precursor and consequently alleviating the progression of CKD [136]. By integrating these different omics data, researchers can attain profound insights into the intricate molecular mechanisms involved in microbiome-host crosstalk.
In addition to exploring the relationship between gut microbiome and CKD, omics contribute to finding the causes and novel diagnosis markers of various kidney diseases. Sethi et al. analyzed the proteomic profile of 12 cases of C3 glomerulonephritis (C3GN). The results showed that alternative pathway (AP) dysregulation can lead to C3GN by causing glomerular accumulation of AP and TCC proteins [137]. Dasari et al. detected proteins in glomerular biopsy specimens of patients by liquid chromatography and tandem mass spectroscopy (LC–MS/MS). They found that DnaJ homolog subfamily B member 9 (DNAJB9) is a specific protein in fibrillary glomerulonephritis, which indicates the role of DNAJB9 in pathogenesis and its potential to be a biomarker [138]. Moreover, metabolomics is used to explore the underlying metabolic pathway in CKD progression. Ma et al. revealed that the overexpression of APOL1 gene, previously demonstrated to be associated with CKD progression, can lead to alterations in the tricarboxylic acid cycle, increased fatty acid oxidation, and compromised redox homeostasis [139].

Potential therapies

Given the close interplay between the gut microbiome and CKD, some therapies target bacteria and its metabolites, which may alter the gut milieu and ameliorate the progression of CKD and its complications.

Probiotics

Probiotics are living microorganisms. It has been accepted that probiotics confer health benefits on gut environment. The underlying mechanisms for the beneficial effects of probiotics on gut health are multifaceted and include the following: (1) Immunomodulation, where specific bacterial strains can exert anti-inflammatory effects by inhibiting NF-κB signaling [140]; (2) Enhancement of the intestinal barrier, as probiotic treatment has been shown to inhibit changes in tight junctions (TJs), which are vital components of the gut barrier [141]; and (3) Resistance to pathogens, as Bacillus subtilis LF11 has been demonstrated to protect epithelial cells by reducing the attachment and invasion of Salmonella [142]. Some probiotics secret bacteriocins to play an antimicrobial role [143].
There are studies showing the beneficial effects of probiotics on CKD. Simenhoff et al. treated 8 HD patients with oral Lactobacillus acidophilus and the results showed reduced serum dimethylamine (DMA) which damages the organ vascular [17, 110]. Moreover, oral administration of Bifidobacterium longum in capsule reduced serum IS levels [144]. Recently, Zhu et al. investigated the therapeutic effects of the probiotic Lactobacillus casei Zhang in both mouse models and patients with CKD. The findings revealed that the administration of L. casei Zhang improved the inflammatory response of local macrophages and tubular epithelia cells by increasing the level of serum SCFAs [145]. Further, the study observed a slower decrease in renal function in patients with CKD stages 3–5 after taking L. casei Zhang [145]. However, due to the extensive variation in diet, disease condition and age of individuals, the therapeutic precision of the probiotics needs to be fully considered.

Prebiotics

Prebiotics are non-digestible food ingredients that improve human health by stimulating the growth of commensal bacteria, such as Lactobacillus and Bifidobacterium [146]. Common prebiotics include resistant starch, inulin, and oligosaccharides such as fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS) [147]. The prebiotics can be metabolized by gut microbiota to produce SCFAs, which in turn can exert beneficial effects. SCFAs play a crucial role in providing an energy source of gut microbiota, regulating the luminal pH and inhibiting the growth of pathogens [148]. Furthermore, GOS protects disrupted gut epithelial and accelerates the TJ reassembly [149]. Oligofructose inulin treatment for four weeks reduced the serum level of pCS in HD patients, with the effect lasting for at least four weeks [150]. Moreover, the association between the ratio of total protein to total fiber and the levels of both IS and pCS is found to be significant, and incorporating this index into the eGFR regression model can improve its predictive power for the levels of uremic toxins [151].
In addition to non-digestible food ingredients, oral sorbents are used to reduce toxins levels. AST-120 is a sorbent with porous carbon particles. Several reports have demonstrated its beneficial effects on ameliorating CKD progression. A study showed that AST-120 reduces serum IS levels and ameliorates oxidative stress in cardiac tissue in CKD rats [152]. Recently, Huang et al. demonstrated that IS could inhibit mitophagy and subsequently cause damage to the intestinal barrier [153]. Mitophagy plays a protective role in healthy cells [154]. The study further revealed that AST-120 can provide protection against mitophagic impairment and intestinal barrier injury in CKD mice models [153]. Furthermore, the efficacy of AST-120 has also been demonstrated in human studies. A study by Nakamura et al. enrolled fifty patients with chronic renal failure, and the effects of AST-120 therapy were evaluated [155]. The results revealed that AST-120 therapy significantly reduced the levels of IL-6 and proteinuria, and inhibited the increase of serum creatinine levels [155]. However, it was observed that the therapy was not effective in preventing the decrease of GFR [155]. More clinical studies have been reviewed elsewhere [156]. Because of the challenges associated with accurately determining the sample size and duration of the study necessary, the evaluation of the effects of AST-120 on the renal hard endpoint is insufficient in many studies. Therefore, more well-designed studies need to be performed.

Synbiotics

Multiple combinations of probiotics and prebiotics have been applied in clinical practices, including OAT fiber/L. plantarum, and FOS/L. sporogens [157]. Synbiotics have the collaborative effects of the prebiotics and probiotics, which has higher efficacy. Probiotics are capable of releasing bacteriocins that inhibit bacteria involved in p-cresol production, while prebiotics can promote the growth of commensal bacteria [158]. A study has reported the efficacy of Probinul-neutro® in reducing serum p-cresol levels in patients with CKD when administered thrice daily for four weeks [159]. Another single-center, double-blind, placebo-controlled, randomized crossover trial study has found that synbiotics significantly reduce serum pCS but not IS in patients with CKD [160]. Moreover, synbiotics can increase Bifidobacterium and decrease Ruminococcaceae in their stool microbial community [160]. Recently, synbiotics have been shown to improve dysbiosis, decrease the amount of fecal indole and ameliorate CKD progression in CKD rat models [161].

Dietary manipulation

A current well-accepted hypothesis is that high-protein diets may be harmful to kidney [162]. The underlying mechanisms include causing hyperfiltration in kidney and upregulating the renal expression of TNF-α and IL-6 [163, 164]. In the Singapore Chinese Health Study, the researcher found that ESRD risk increases with an increased intake of red meat [165]. Moreover, most foods with high protein contain phosphate, which will disturb the serum phosphate level in the early stages of CKD [166]. On the contrary, the restriction of dietary protein can reduce sclerosis in kidney [167]. Therefore, many experts recommend a plant-dominant low-protein diet for patients with CKD [168]. In a meta-analysis, researchers found that CKD patients had lower mortality when adopting a healthy diet rich in fruit and vegetables, fish, legumes, cereals, whole grains, and fiber, and less in red meat and products containing sodium and refined sugars [152]. Furthermore, high-fiber diets contribute to the growth of beneficial bacteria such as Bacteroidetes that are capable of producing SCFAs [153]. These SCFAs can improve gut dysbiosis. Given the powerful role of diet–microbiota–host crosstalk, dietary manipulation could be an effective therapeutic tool [154].

Genetic engineering

In 2015, Sonnenburg proposed the concept of ‘‘smart’’ bacteria that can secrete anti-inflammatory molecules [169]. In recent years, genetic engineering technology has been also applied to reduce toxins and ameliorate disease. Devlin et al. discovered a family of tryptophanases widely distributed in the gut commensal Bacteroides [170]. Through the deletion of this gene, they were able to eliminate indole production in vivo [170]. Moreover, researchers have successfully designed microencapsulated genetically engineered live E.coli DH5 cells [171]. They demonstrated the effective reduction of urea levels in uremic rats upon oral administration of the products [171]. Besides, Steidler et al. designed Lactococcus lactis to secret IL-10 in the colon [172]. When this engineered Lactococcus lactis was orally administered, it was found to have a beneficial effect on reducing inflammation in colitis mouse models [172]. Recently, Ting et al. showed an innovative method to deplete a specific bacterium from gut flora. They designed E. cloacae strains expressing nanobodies, called programmed inhibitor cells (PICs) [173]. PICs recognize target bacteria via surface nanobodies and eradicate it from gut microbiota [173]. Even though microbiota engineering is far from clinical application, it may be a promising way to achieve precision medicine.

Fecal microbiota transplantation

Fecal microbiota transplantation (FMT) involves the transfer of gut microbiota from a healthy donor to a patient by infusing donor feces into the patient. It aims to restore the disturbed gut microbiota in patients. Therapeutic effects of FMT have been first demonstrated in the treatment of recurrent Clostridium difficile infection (CDI) [174]. The US Food and Drug Administration (FDA) permits the administration of FMT to CDI that does not respond to standard therapies [175]. Subsequently, there are increasing reports of the efficacy of FMT on other diseases [176]. A study found that FMT can decrease albuminuria and modulate renal phenotype in antibiotic-treated humanized IgAN mice [177]. In addition to effectiveness, a study has investigated the occurrence of adverse events (AEs) of FMT. A systematic analysis of cases published between 1983 and 2015 suggested an overall incidence of AEs was 28.5% (310/1089) [178]. Most of the AEs were mild, including abdominal discomfort, diarrhea, transient fever, nausea, vomiting and constipation [178]. The findings indicate that FMT is generally safe. However, rare but severe AEs have been reported, such as death, severe infections, and relapse of inflammatory bowel diseases (IBD) [178]. The risk of infections is associated with the inability of screening latent infection of donors [178]. Therefore, FDA has issued a warning on the risk of FMT [179]. More rigorous studies are required to assess the short- and long-term risks and efficacy of FMT.

Challenges and perspectives

As a result of technological advancements, the intricacies of the gut microbiome have been partly elucidated, revealing the involvement of gut microbiota and its metabolites in the progression of CKD. In particular, PBUTs have been identified as contributors to immune dysfunction with adverse effects on CKD and its complications. Thus, novel interventions that aim to mitigate or even eliminate these detrimental effects should be developed. As noted, genetic engineering is a promising technology. Targeting enzymes that involve in PBUTs production by utilizing genetic engineering may be a feasible avenue. Integrating this approach with the assessment of efficacy in ameliorating immune dysfunction and CKD progression may help with the design of therapeutic strategies.
Current treatments aim to reduce the levels of PBUTs and regulate dysbiosis through dietary restriction and synbiotics. However, these therapies are limited by inter-individual variabilities in diet, lifestyle, age, and medication. Therefore, personalized therapeutic strategies based on a patient’s status are needed. Long-term and continuous follow-up is also required to yield clinically meaningful results. Despite these challenges, the gut microbiome in patients with CKD represents an exciting area of research. The microbiome-based treatments show promise in improving clinical practice and outcomes of patients with CKD.

Acknowledgements

Not applicable.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107–33.PubMed Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107–33.PubMed
2.
Zurück zum Zitat Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.PubMedPubMedCentral Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.PubMedPubMedCentral
3.
Zurück zum Zitat Lynch SV, Pedersen O. The Human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–79.PubMed Lynch SV, Pedersen O. The Human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–79.PubMed
4.
Zurück zum Zitat Chen Y-Y, Chen D-Q, Chen L, Liu J-R, Vaziri ND, Guo Y, Zhao YY. Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. J Transl Med. 2019;17:5.PubMedPubMedCentral Chen Y-Y, Chen D-Q, Chen L, Liu J-R, Vaziri ND, Guo Y, Zhao YY. Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. J Transl Med. 2019;17:5.PubMedPubMedCentral
5.
Zurück zum Zitat Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen T-H, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83:308–15.PubMed Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen T-H, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83:308–15.PubMed
6.
Zurück zum Zitat Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39:230–7.PubMed Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39:230–7.PubMed
7.
Zurück zum Zitat Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int. 1995;47:510–7.PubMed Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int. 1995;47:510–7.PubMed
8.
Zurück zum Zitat Vaziri ND, Goshtasbi N, Yuan J, Jellbauer S, Moradi H, Raffatellu M, Kalantar-Zadeh K. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012;36:438–43.PubMed Vaziri ND, Goshtasbi N, Yuan J, Jellbauer S, Moradi H, Raffatellu M, Kalantar-Zadeh K. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012;36:438–43.PubMed
9.
Zurück zum Zitat Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T, Motojima M. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol. 2003;95:e111-118.PubMed Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T, Motojima M. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol. 2003;95:e111-118.PubMed
10.
Zurück zum Zitat Sun C-Y, Chang S-C, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin–angiotensin–aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE. 2012;7: e34026.PubMedPubMedCentral Sun C-Y, Chang S-C, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin–angiotensin–aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE. 2012;7: e34026.PubMedPubMedCentral
11.
Zurück zum Zitat Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, Noguchi T, Kadowaki D, Ishima Y, Kotani S, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013;83:582–92.PubMed Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, Noguchi T, Kadowaki D, Ishima Y, Kotani S, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013;83:582–92.PubMed
12.
Zurück zum Zitat Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048–50.PubMed Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048–50.PubMed
15.
Zurück zum Zitat McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019;30:127.PubMed McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019;30:127.PubMed
16.
Zurück zum Zitat Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68:S57–65. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68:S57–65.
17.
Zurück zum Zitat Fujii H, Goto S, Fukagawa M. Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins. 2018;10:E202. Fujii H, Goto S, Fukagawa M. Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins. 2018;10:E202.
18.
Zurück zum Zitat Betjes MGH. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013;9:255–65.PubMed Betjes MGH. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013;9:255–65.PubMed
19.
Zurück zum Zitat Lorne E, Dupont H, Abraham E. Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? Intensive Care Med. 2010;36:1826–35.PubMedPubMedCentral Lorne E, Dupont H, Abraham E. Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? Intensive Care Med. 2010;36:1826–35.PubMedPubMedCentral
20.
Zurück zum Zitat Gollapudi P, Yoon J-W, Gollapudi S, Pahl MV, Vaziri ND. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol. 2010;31:247–54.PubMed Gollapudi P, Yoon J-W, Gollapudi S, Pahl MV, Vaziri ND. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol. 2010;31:247–54.PubMed
21.
Zurück zum Zitat Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–8.PubMed Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–8.PubMed
22.
Zurück zum Zitat Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMed Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMed
23.
Zurück zum Zitat Jeng Y, Lim PS, Wu MY, Tseng T-Y, Chen CH, Chen HP, Wu TK. Proportions of proinflammatory monocytes are important predictors of mortality risk in hemodialysis patients. Mediators Inflamm. 2017;2017: e1070959. Jeng Y, Lim PS, Wu MY, Tseng T-Y, Chen CH, Chen HP, Wu TK. Proportions of proinflammatory monocytes are important predictors of mortality risk in hemodialysis patients. Mediators Inflamm. 2017;2017: e1070959.
24.
Zurück zum Zitat Yadav AK, Jha V. CD4+CD28null cells are expanded and exhibit a cytolytic profile in end-stage renal disease patients on peritoneal dialysis. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2011;26:1689–94. Yadav AK, Jha V. CD4+CD28null cells are expanded and exhibit a cytolytic profile in end-stage renal disease patients on peritoneal dialysis. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2011;26:1689–94.
25.
Zurück zum Zitat Pahl MV, Vaziri ND, Yuan J. Adler SG upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol CJASN. 2010;5:56–61.PubMed Pahl MV, Vaziri ND, Yuan J. Adler SG upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol CJASN. 2010;5:56–61.PubMed
26.
Zurück zum Zitat Betjes MGH, de Wit EEA, Weimar W, Litjens NHR. Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2010;25:3640–6. Betjes MGH, de Wit EEA, Weimar W, Litjens NHR. Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2010;25:3640–6.
27.
Zurück zum Zitat Talal S, Mona K, Karem A, Yaniv L, Reut H-M, Ariel S, Moran A-K, Harel E, Campisi-Pinto S, Mahmoud A-A, et al. Neutrophil degranulation and severely impaired extracellular trap formation at the basis of susceptibility to infections of hemodialysis patients. BMC Med. 2022;20:364.PubMedPubMedCentral Talal S, Mona K, Karem A, Yaniv L, Reut H-M, Ariel S, Moran A-K, Harel E, Campisi-Pinto S, Mahmoud A-A, et al. Neutrophil degranulation and severely impaired extracellular trap formation at the basis of susceptibility to infections of hemodialysis patients. BMC Med. 2022;20:364.PubMedPubMedCentral
28.
Zurück zum Zitat Verkade MA, van de Wetering J, Klepper M, Vaessen LMB, Weimar W, Betjes MGH. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int. 2004;66:614–21.PubMed Verkade MA, van de Wetering J, Klepper M, Vaessen LMB, Weimar W, Betjes MGH. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int. 2004;66:614–21.PubMed
29.
Zurück zum Zitat Syed-Ahmed, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26:8–15.PubMed Syed-Ahmed, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26:8–15.PubMed
30.
Zurück zum Zitat Bowry SK, Kotanko P, Himmele R, Tao X, Anger M. The membrane perspective of uraemic toxins: which ones should, or can, be removed? Clin Kidney J. 2021;14:i17–31.PubMedPubMedCentral Bowry SK, Kotanko P, Himmele R, Tao X, Anger M. The membrane perspective of uraemic toxins: which ones should, or can, be removed? Clin Kidney J. 2021;14:i17–31.PubMedPubMedCentral
31.
Zurück zum Zitat Ho-dac-Pannekeet MM, Koopmans JG, Struijk DG, Krediet RT. Restriction coefficients of low molecular weight solutes and macromolecules during peritoneal dialysis. Adv Peritoneal Dialysis Conf Peritoneal Dialysis. 1997;13:72–6. Ho-dac-Pannekeet MM, Koopmans JG, Struijk DG, Krediet RT. Restriction coefficients of low molecular weight solutes and macromolecules during peritoneal dialysis. Adv Peritoneal Dialysis Conf Peritoneal Dialysis. 1997;13:72–6.
32.
Zurück zum Zitat Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int. 2006;70:794–9.PubMed Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int. 2006;70:794–9.PubMed
33.
Zurück zum Zitat Krieter DH, Kerwagen S, Rüth M, Lemke H-D, Wanner C. Differences in dialysis efficacy have limited effects on protein-bound uremic toxins plasma levels over time. Toxins. 2019;11:47.PubMedPubMedCentral Krieter DH, Kerwagen S, Rüth M, Lemke H-D, Wanner C. Differences in dialysis efficacy have limited effects on protein-bound uremic toxins plasma levels over time. Toxins. 2019;11:47.PubMedPubMedCentral
34.
Zurück zum Zitat Snauwaert E, Van Biesen W, Raes A, Glorieux G, Walle JV, Roels S, Vanholder R, Askiti V, Azukaitis K, Bayazit A, Canpolat N, Fischbach M, Saoussen K, Litwin M, Obrycki L, Paglialonga F, Ranchin B, Samaille C, Schaefer F, Schmitt CP, Spasojevic B, Stefanidis CJ, Shroff R, Eloot S. Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population. Nephrol Dialysis Trans Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2020;35(648):656. Snauwaert E, Van Biesen W, Raes A, Glorieux G, Walle JV, Roels S, Vanholder R, Askiti V, Azukaitis K, Bayazit A, Canpolat N, Fischbach M, Saoussen K, Litwin M, Obrycki L, Paglialonga F, Ranchin B, Samaille C, Schaefer F, Schmitt CP, Spasojevic B, Stefanidis CJ, Shroff R, Eloot S. Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population. Nephrol Dialysis Trans Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2020;35(648):656.
36.
Zurück zum Zitat Stockinger B, Meglio PD, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–32.PubMed Stockinger B, Meglio PD, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–32.PubMed
37.
Zurück zum Zitat Lemos DR, McMurdo M, Karaca G, Wilflingseder J, Leaf IA, Gupta N, Miyoshi T, Susa K, Johnson BG, Soliman K, et al. Interleukin-1β activates a MYC-dependent metabolic switch in kidney stromal cells necessary for progressive tubulointerstitial fibrosis. J Am Soc Nephrol. 2018;29:1690–705.PubMedPubMedCentral Lemos DR, McMurdo M, Karaca G, Wilflingseder J, Leaf IA, Gupta N, Miyoshi T, Susa K, Johnson BG, Soliman K, et al. Interleukin-1β activates a MYC-dependent metabolic switch in kidney stromal cells necessary for progressive tubulointerstitial fibrosis. J Am Soc Nephrol. 2018;29:1690–705.PubMedPubMedCentral
38.
Zurück zum Zitat Kim HY, Yoo T-H, Hwang Y, Lee GH, Kim B, Jang J, Yu HT, Kim MC, Cho J-Y, Lee CJ, et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci Rep. 2017;7:3057.PubMedPubMedCentral Kim HY, Yoo T-H, Hwang Y, Lee GH, Kim B, Jang J, Yu HT, Kim MC, Cho J-Y, Lee CJ, et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci Rep. 2017;7:3057.PubMedPubMedCentral
39.
Zurück zum Zitat Kim HY, Yoo T-H, Cho J-Y, Kim HC, Lee WW. Indoxyl sulfate–induced TNF-α is regulated by crosstalk between the aryl hydrocarbon receptor, NF-κB, and SOCS2 in human macrophages. FASEB J. 2019;33:10844–58.PubMed Kim HY, Yoo T-H, Cho J-Y, Kim HC, Lee WW. Indoxyl sulfate–induced TNF-α is regulated by crosstalk between the aryl hydrocarbon receptor, NF-κB, and SOCS2 in human macrophages. FASEB J. 2019;33:10844–58.PubMed
40.
Zurück zum Zitat Lee C-T, Kuo C-C, Chen Y-M, Hsu C-Y, Lee W-C, Tsai Y-C, Ng H-Y, Kuo L-C, Chiou TT-Y, Yang Y-K, et al. Factors associated with blood concentrations of indoxyl sulfate and p—cresol in patients undergoing peritoneal dialysis peritoneal dialysis international. J Int Soc Peritoneal Dialysis. 2010;30:456–63. Lee C-T, Kuo C-C, Chen Y-M, Hsu C-Y, Lee W-C, Tsai Y-C, Ng H-Y, Kuo L-C, Chiou TT-Y, Yang Y-K, et al. Factors associated with blood concentrations of indoxyl sulfate and p—cresol in patients undergoing peritoneal dialysis peritoneal dialysis international. J Int Soc Peritoneal Dialysis. 2010;30:456–63.
41.
Zurück zum Zitat Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Landschoot MV, Eloot S, Rops Voorde A, Vriese AD, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013;24(1981):1994. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Landschoot MV, Eloot S, Rops Voorde A, Vriese AD, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013;24(1981):1994.
42.
Zurück zum Zitat Hubbard TD, Murray IA, Perdew GH. Indole and tryptophan metabolism: endogenous and dietary routes to ah receptor activation. Drug Metab Dispos. 2015;43:1522–35.PubMedPubMedCentral Hubbard TD, Murray IA, Perdew GH. Indole and tryptophan metabolism: endogenous and dietary routes to ah receptor activation. Drug Metab Dispos. 2015;43:1522–35.PubMedPubMedCentral
43.
Zurück zum Zitat de Melo M, Curi T, Miyasaka C, Palanch A, Curi R. Effect of indole acetic acid on oxygen metabolism in cultured rat neutrophil. General Pharmacol Vascul Syst. 1998;31:573–8. de Melo M, Curi T, Miyasaka C, Palanch A, Curi R. Effect of indole acetic acid on oxygen metabolism in cultured rat neutrophil. General Pharmacol Vascul Syst. 1998;31:573–8.
44.
Zurück zum Zitat Salopek-Sondi B, Piljac-Žegarac J, Magnus V, Kopjar N. Free radical–scavenging activity and DNA damaging potential of auxins IAA and 2-methyl-IAA evaluated in human neutrophils by the alkaline comet assay. J Biochem Mol Toxicol. 2010;24:165–73.PubMed Salopek-Sondi B, Piljac-Žegarac J, Magnus V, Kopjar N. Free radical–scavenging activity and DNA damaging potential of auxins IAA and 2-methyl-IAA evaluated in human neutrophils by the alkaline comet assay. J Biochem Mol Toxicol. 2010;24:165–73.PubMed
45.
Zurück zum Zitat Dou L, Sallée M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, Fallague K, Brunet P, Calaf R, Dussol B, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol. 2015;26:876–87.PubMed Dou L, Sallée M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, Fallague K, Brunet P, Calaf R, Dussol B, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol. 2015;26:876–87.PubMed
46.
Zurück zum Zitat Schepers E, Glorieux G, Vanholder R. The gut the forgotten organ in uremia? Blood Purif. 2010;29:130–6.PubMed Schepers E, Glorieux G, Vanholder R. The gut the forgotten organ in uremia? Blood Purif. 2010;29:130–6.PubMed
47.
Zurück zum Zitat Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2007;22:592–6.PubMed Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2007;22:592–6.PubMed
48.
Zurück zum Zitat Azevedo MLV, Bonan NB, Dias G, Brehm F, Steiner TM, Souza WM, Stinghen AEM, Barreto FC, Elifio-Esposito S, Pecoits-Filho R, Moreno-Amaral AN. p-Cresyl sulfate affects the oxidative burst, phagocytosis process, and antigen presentation of monocyte-derived macrophages. Toxicol Lett. 2016;263:1–5.PubMed Azevedo MLV, Bonan NB, Dias G, Brehm F, Steiner TM, Souza WM, Stinghen AEM, Barreto FC, Elifio-Esposito S, Pecoits-Filho R, Moreno-Amaral AN. p-Cresyl sulfate affects the oxidative burst, phagocytosis process, and antigen presentation of monocyte-derived macrophages. Toxicol Lett. 2016;263:1–5.PubMed
49.
Zurück zum Zitat Shiba T, Kawakami K, Sasaki T, Makino I, Kato I, Kobayashi T, Uchida K, Kaneko K. Effects of intestinal bacteria-derived p-cresyl sulfate on Th1-type immune response in vivo and in vitro. Toxicol Appl Pharmacol. 2014;274:191–9.PubMed Shiba T, Kawakami K, Sasaki T, Makino I, Kato I, Kobayashi T, Uchida K, Kaneko K. Effects of intestinal bacteria-derived p-cresyl sulfate on Th1-type immune response in vivo and in vitro. Toxicol Appl Pharmacol. 2014;274:191–9.PubMed
50.
Zurück zum Zitat Kawakami K, Makino I, Kato I, Uchida K, Onoue M. p-Cresol inhibits IL-12 production by murine macrophages stimulated with bacterial immunostimulant. Immunopharmacol Immunotoxicol. 2009;31:304–9.PubMed Kawakami K, Makino I, Kato I, Uchida K, Onoue M. p-Cresol inhibits IL-12 production by murine macrophages stimulated with bacterial immunostimulant. Immunopharmacol Immunotoxicol. 2009;31:304–9.PubMed
51.
Zurück zum Zitat Shiba T, Makino I, Sasaki T, Fukuhara Y, Kawakami K, Kato I, Kobayashi T. p-Cresyl sulfate decreases peripheral B cells in mice with adenine-induced renal dysfunction. Toxicol Appl Pharmacol. 2018;342:50–9.PubMed Shiba T, Makino I, Sasaki T, Fukuhara Y, Kawakami K, Kato I, Kobayashi T. p-Cresyl sulfate decreases peripheral B cells in mice with adenine-induced renal dysfunction. Toxicol Appl Pharmacol. 2018;342:50–9.PubMed
52.
Zurück zum Zitat Beaman M, Michael J, MacLennan IC, Adu D. T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure. Nephrol Dialysis Transpl Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc. 1989;4:216–21. Beaman M, Michael J, MacLennan IC, Adu D. T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure. Nephrol Dialysis Transpl Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc. 1989;4:216–21.
53.
Zurück zum Zitat Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. 2009;76:S12–9. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. 2009;76:S12–9.
54.
Zurück zum Zitat Wu IW, Lin CY, Chang LC, Lee CC, Chiu CY, Hsu HJ, Sun CY, Chen YC, Kuo YL, Yang CW, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16:420–34.PubMedPubMedCentral Wu IW, Lin CY, Chang LC, Lee CC, Chiu CY, Hsu HJ, Sun CY, Chen YC, Kuo YL, Yang CW, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16:420–34.PubMedPubMedCentral
55.
Zurück zum Zitat Bolati D, Shimizu H, Higashiyama Y, Nishijima F, Niwa T. Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol. 2011;34:318–23.PubMed Bolati D, Shimizu H, Higashiyama Y, Nishijima F, Niwa T. Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol. 2011;34:318–23.PubMed
56.
Zurück zum Zitat Poveda J, Sanchez-Niño MD, Glorieux G, Sanz AB, Egido J, Vanholder R, Ortiz A. p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dialysis Transpl Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc. 2014;29:56–64. Poveda J, Sanchez-Niño MD, Glorieux G, Sanz AB, Egido J, Vanholder R, Ortiz A. p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dialysis Transpl Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc. 2014;29:56–64.
57.
Zurück zum Zitat Sun C-Y, Chang S-C, Wu M-S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 2012;81:640–50.PubMedPubMedCentral Sun C-Y, Chang S-C, Wu M-S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 2012;81:640–50.PubMedPubMedCentral
58.
Zurück zum Zitat Sun C-Y, Hsu H-H, Wu M-S. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant. 2013;28:70–8.PubMed Sun C-Y, Hsu H-H, Wu M-S. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant. 2013;28:70–8.PubMed
59.
Zurück zum Zitat Wiley SR, Winkles JA. A member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241–9.PubMed Wiley SR, Winkles JA. A member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241–9.PubMed
60.
Zurück zum Zitat Li H-B, Xu M-L, Xu X-D, Tang Y-Y, Jiang H-L, Li L, Xia W-J, Cui N, Bai J, Dai Z-M, et al. Faecalibacterium prausnitzii attenuates CKD via butyrate-renal GPR43 axis. Circ Res. 2022;131:e120–34.PubMedPubMedCentral Li H-B, Xu M-L, Xu X-D, Tang Y-Y, Jiang H-L, Li L, Xia W-J, Cui N, Bai J, Dai Z-M, et al. Faecalibacterium prausnitzii attenuates CKD via butyrate-renal GPR43 axis. Circ Res. 2022;131:e120–34.PubMedPubMedCentral
61.
Zurück zum Zitat Gonzalez A, Krieg R, Massey HD, Carl D, Ghosh S, Gehr TWB, Ghosh SS. Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression. Nephrol Dial Transpl. 2019;34:783–94. Gonzalez A, Krieg R, Massey HD, Carl D, Ghosh S, Gehr TWB, Ghosh SS. Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression. Nephrol Dial Transpl. 2019;34:783–94.
62.
Zurück zum Zitat Al-Harbi NO, Nadeem A, Ahmad SF, Alotaibi MR, AlAsmari AF, Alanazi WA, Al-Harbi MM, El-Sherbeeny AM, Ibrahim KE. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells. Int Immunopharmacol. 2018;58:24–31.PubMed Al-Harbi NO, Nadeem A, Ahmad SF, Alotaibi MR, AlAsmari AF, Alanazi WA, Al-Harbi MM, El-Sherbeeny AM, Ibrahim KE. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells. Int Immunopharmacol. 2018;58:24–31.PubMed
63.
Zurück zum Zitat Mikami D, Kobayashi M, Uwada J, Yazawa T, Kamiyama K, Nishimori K, Nishikawa Y, Nishikawa S, Yokoi S, Kimura H, et al. 2020. Short-chain fatty acid mitigates adenine-induced chronic kidney disease via FFA2 and FFA3 pathways. Biochimica et Biophysica Acta (BBA) Molecular and Cell Biology of Lipids. 65: 158666. Mikami D, Kobayashi M, Uwada J, Yazawa T, Kamiyama K, Nishimori K, Nishikawa Y, Nishikawa S, Yokoi S, Kimura H, et al. 2020. Short-chain fatty acid mitigates adenine-induced chronic kidney disease via FFA2 and FFA3 pathways. Biochimica et Biophysica Acta (BBA) Molecular and Cell Biology of Lipids. 65: 158666.
64.
Zurück zum Zitat Marzocco S, Fazeli G, Di Micco L, Autore G, Adesso S, Dal Piaz F, Heidland A. Supplementation of short-chain fatty acid, sodium propionate, in patients on maintenance hemodialysis: beneficial effects on inflammatory parameters and gut-derived uremic toxins, a pilot study (PLAN Study). J Clin Med. 2018;7:315.PubMedPubMedCentral Marzocco S, Fazeli G, Di Micco L, Autore G, Adesso S, Dal Piaz F, Heidland A. Supplementation of short-chain fatty acid, sodium propionate, in patients on maintenance hemodialysis: beneficial effects on inflammatory parameters and gut-derived uremic toxins, a pilot study (PLAN Study). J Clin Med. 2018;7:315.PubMedPubMedCentral
65.
Zurück zum Zitat Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.PubMed Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.PubMed
66.
Zurück zum Zitat Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.PubMedPubMedCentral Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.PubMedPubMedCentral
67.
Zurück zum Zitat Hu X, Du J, Xie Y, Huang Q, Xiao Y, Chen J, Yan S, Gong Z, Ouyang S. Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study. BMC Nephrol. 2020;21:97.PubMedPubMedCentral Hu X, Du J, Xie Y, Huang Q, Xiao Y, Chen J, Yan S, Gong Z, Ouyang S. Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study. BMC Nephrol. 2020;21:97.PubMedPubMedCentral
68.
Zurück zum Zitat De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G, Serrazanetti D, Dalfino G, Gobbetti M, Gesualdo L. Microbiota and metabolome associated with immunoglobulin a nephropathy (IgAN). PLoS ONE. 2014;9: e99006.PubMedPubMedCentral De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G, Serrazanetti D, Dalfino G, Gobbetti M, Gesualdo L. Microbiota and metabolome associated with immunoglobulin a nephropathy (IgAN). PLoS ONE. 2014;9: e99006.PubMedPubMedCentral
69.
Zurück zum Zitat Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2008;23:1608–14. Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2008;23:1608–14.
70.
Zurück zum Zitat Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA. 2002;99:16613–8.PubMedPubMedCentral Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA. 2002;99:16613–8.PubMedPubMedCentral
71.
Zurück zum Zitat Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Investig. 1999;104:73–81.PubMedPubMedCentral Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Investig. 1999;104:73–81.PubMedPubMedCentral
72.
Zurück zum Zitat McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MAE, Macpherson AJ, McCoy KD, et al. Mice overexpressing BAFF develop a commensal flora-dependent. IgA-Assoc Nephropathy J Clin Investig. 2011;121:3991–4002.PubMed McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MAE, Macpherson AJ, McCoy KD, et al. Mice overexpressing BAFF develop a commensal flora-dependent. IgA-Assoc Nephropathy J Clin Investig. 2011;121:3991–4002.PubMed
73.
Zurück zum Zitat Han L, Fang X, He Y, Ruan XZ. Forefronts symposium iga nephropathy, the gut microbiota, and gut−kidney crosstalk. Kidney Int Rep. 2015;1(189):196. Han L, Fang X, He Y, Ruan XZ. Forefronts symposium iga nephropathy, the gut microbiota, and gut−kidney crosstalk. Kidney Int Rep. 2015;1(189):196.
74.
Zurück zum Zitat Zhong Z, Tan J, Tan L, Tang Y, Qiu Z, Pei G, Qin W. Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population. Int Immunopharmacol. 2020;89: 107085.PubMed Zhong Z, Tan J, Tan L, Tang Y, Qiu Z, Pei G, Qin W. Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population. Int Immunopharmacol. 2020;89: 107085.PubMed
75.
Zurück zum Zitat Chemouny JM, Gleeson PJ, Abbad L, Lauriero G, Le Boedec E, Roux K, Monot C, Bredel M, Bex-Coudrat J, Sannier A, et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin a nephropathy in humanized mice. Nephrol Dial Transpl. 2019;34(1135):1144. Chemouny JM, Gleeson PJ, Abbad L, Lauriero G, Le Boedec E, Roux K, Monot C, Bredel M, Bex-Coudrat J, Sannier A, et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin a nephropathy in humanized mice. Nephrol Dial Transpl. 2019;34(1135):1144.
76.
Zurück zum Zitat Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai C-Y, Floyd T, Al-Aly Z. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease. Kidney Int. 2018;94(567):581. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai C-Y, Floyd T, Al-Aly Z. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease. Kidney Int. 2018;94(567):581.
77.
Zurück zum Zitat Gross JL, de Azevedo MJ, Silveiro SP, Henrique Canani L, Luiza Caramori M, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(164):176. Gross JL, de Azevedo MJ, Silveiro SP, Henrique Canani L, Luiza Caramori M, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(164):176.
78.
Zurück zum Zitat Urushihara M, Kagami S. Role of the intrarenal renin–angiotensin system in the progression of renal disease. Pediatr Nephrol. 2017;32(1471):1479. Urushihara M, Kagami S. Role of the intrarenal renin–angiotensin system in the progression of renal disease. Pediatr Nephrol. 2017;32(1471):1479.
79.
Zurück zum Zitat Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58:259–71.PubMed Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58:259–71.PubMed
80.
Zurück zum Zitat Chen-chen L, Ze-bo H, Wang R, Hong Ze, Jian L, Chen P, Zhang J, Li X, Yuan B, Huang S, Ruan X, Liu B, Ma K. Gut microbiota dysbiosis-induced activation of the intrarenal renin–angiotensin system is involved in kidney injuries in rat diabetic nephropathy. Acta Pharmacol Sin. 2020;41(1111):1118. Chen-chen L, Ze-bo H, Wang R, Hong Ze, Jian L, Chen P, Zhang J, Li X, Yuan B, Huang S, Ruan X, Liu B, Ma K. Gut microbiota dysbiosis-induced activation of the intrarenal renin–angiotensin system is involved in kidney injuries in rat diabetic nephropathy. Acta Pharmacol Sin. 2020;41(1111):1118.
81.
Zurück zum Zitat Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan L-X, Rey F, Wang T, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci. 2013;110:4410–5.PubMedPubMedCentral Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan L-X, Rey F, Wang T, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci. 2013;110:4410–5.PubMedPubMedCentral
82.
Zurück zum Zitat Hu ZB, Lu J, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, Ruan XZ, Liu BC. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics. 2020;10:2803–16.PubMedPubMedCentral Hu ZB, Lu J, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, Ruan XZ, Liu BC. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics. 2020;10:2803–16.PubMedPubMedCentral
83.
Zurück zum Zitat Lu J, Chen PP, Zhang JX, Li XQ, Wang GH, Yuan BY, Huang SJ, Liu XQ, Jiang TT, Wang MY, et al. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity. Theranostics. 2021;11:4728–42.PubMedPubMedCentral Lu J, Chen PP, Zhang JX, Li XQ, Wang GH, Yuan BY, Huang SJ, Liu XQ, Jiang TT, Wang MY, et al. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity. Theranostics. 2021;11:4728–42.PubMedPubMedCentral
84.
Zurück zum Zitat Dai H, Liu Q, Liu B. Research progress on mechanism of podocyte depletion in diabetic nephropathy. J Diabetes Res. 2017;2017:2615286.PubMedPubMedCentral Dai H, Liu Q, Liu B. Research progress on mechanism of podocyte depletion in diabetic nephropathy. J Diabetes Res. 2017;2017:2615286.PubMedPubMedCentral
85.
Zurück zum Zitat The diabetic kidney. Totowa. NJ: Humana Press; 2006. The diabetic kidney. Totowa. NJ: Humana Press; 2006.
86.
Zurück zum Zitat Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2022;14:166. Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2022;14:166.
87.
Zurück zum Zitat Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler AC, Barak O, Elazar M, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. 2018;359:1376–83.PubMed Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler AC, Barak O, Elazar M, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. 2018;359:1376–83.PubMed
88.
Zurück zum Zitat Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMed Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMed
89.
Zurück zum Zitat Linh HT, Iwata Y, Senda Y, Sakai-Takemori Y, Nakade Y, Oshima M, Nakagawa-Yoneda S, Ogura H, Sato K, Minami T, et al. Intestinal bacterial translocation contributes to diabetic kidney disease. J Am Soc Nephrol. 2022;33:1105–19.PubMedPubMedCentral Linh HT, Iwata Y, Senda Y, Sakai-Takemori Y, Nakade Y, Oshima M, Nakagawa-Yoneda S, Ogura H, Sato K, Minami T, et al. Intestinal bacterial translocation contributes to diabetic kidney disease. J Am Soc Nephrol. 2022;33:1105–19.PubMedPubMedCentral
90.
Zurück zum Zitat Fischer JC, Bscheider M, Eisenkolb G, Lin C-C, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, et al. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Sci Trans Med. 2017;9:2513. Fischer JC, Bscheider M, Eisenkolb G, Lin C-C, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, et al. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Sci Trans Med. 2017;9:2513.
91.
Zurück zum Zitat Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, Mise K, Yamaguchi H, Nakamura T, Asaji K, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10:1–17. Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, Mise K, Yamaguchi H, Nakamura T, Asaji K, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10:1–17.
92.
Zurück zum Zitat Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69(1780):1785. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69(1780):1785.
93.
Zurück zum Zitat Chen J-H, Chao C-T, Huang J-W, Hung K-Y, Liu S-H, Tarng D-C, Chiang C-K. Early elimination of uremic toxin ameliorates AKI-to-CKD transition. Clin Sci. 2021;135:2643–58. Chen J-H, Chao C-T, Huang J-W, Hung K-Y, Liu S-H, Tarng D-C, Chiang C-K. Early elimination of uremic toxin ameliorates AKI-to-CKD transition. Clin Sci. 2021;135:2643–58.
94.
Zurück zum Zitat Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11:264–76.PubMedPubMedCentral Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11:264–76.PubMedPubMedCentral
95.
Zurück zum Zitat Pral LP, Fachi JL, Corrêa RO, Colonna M, Vinolo MAR. Hypoxia and HIF-1 as key regulators of gut microbiota and host interactions. Trends Immunol. 2021;42:604–21.PubMedPubMedCentral Pral LP, Fachi JL, Corrêa RO, Colonna M, Vinolo MAR. Hypoxia and HIF-1 as key regulators of gut microbiota and host interactions. Trends Immunol. 2021;42:604–21.PubMedPubMedCentral
96.
Zurück zum Zitat Yang J, Kim CJ, Go YS, Lee HY, Kim M-G, Oh SW, Cho WY, Im S-H, Jo SK. Intestinal microbiota control acute kidney injury severity by immune modulation. Kidney Int. 2020;98:932–46.PubMed Yang J, Kim CJ, Go YS, Lee HY, Kim M-G, Oh SW, Cho WY, Im S-H, Jo SK. Intestinal microbiota control acute kidney injury severity by immune modulation. Kidney Int. 2020;98:932–46.PubMed
97.
Zurück zum Zitat Vallon V. Tubular transport in acute kidney injury: relevance for diagnosis. Prognosis Int Nephron. 2016;134:160–6. Vallon V. Tubular transport in acute kidney injury: relevance for diagnosis. Prognosis Int Nephron. 2016;134:160–6.
98.
Zurück zum Zitat Wang I-K, Lai H-C, Yu C-J, Liang C-C, Chang C-T, Kuo H-L, Yang Y-F, Lin C-C, Lin H-H, Liu Y-L, et al. Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Microbiol. 2012;78:1107–12.PubMedPubMedCentral Wang I-K, Lai H-C, Yu C-J, Liang C-C, Chang C-T, Kuo H-L, Yang Y-F, Lin C-C, Lin H-H, Liu Y-L, et al. Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Microbiol. 2012;78:1107–12.PubMedPubMedCentral
99.
Zurück zum Zitat Simões-Silva L, Araujo R, Pestana M, Soares-Silva I, Sampaio-Maia B. The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis. Pharmacol Res. 2018;130:143–51.PubMed Simões-Silva L, Araujo R, Pestana M, Soares-Silva I, Sampaio-Maia B. The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis. Pharmacol Res. 2018;130:143–51.PubMed
100.
Zurück zum Zitat Juergensen PH, Finkelstein FO, Brennan R, Santacroce S, Ahern MJ. Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. Am J Kidney Dis. 1988;11:413–7.PubMed Juergensen PH, Finkelstein FO, Brennan R, Santacroce S, Ahern MJ. Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. Am J Kidney Dis. 1988;11:413–7.PubMed
101.
Zurück zum Zitat Szeto C, Chow VCY, Chow KM, Lai RWM, Chung KY, Leung CB, Kwan BCH, Li PKT. PK-T enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int. 2006;69(1245):1252. Szeto C, Chow VCY, Chow KM, Lai RWM, Chung KY, Leung CB, Kwan BCH, Li PKT. PK-T enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int. 2006;69(1245):1252.
102.
Zurück zum Zitat Bossola M, Sanguinetti M, Scribano D, Zuppi C, Giungi S, Luciani G, Torelli R, Posteraro B, Fadda G, Tazza L. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. CJASN. 2009;4:379–85.PubMedPubMedCentral Bossola M, Sanguinetti M, Scribano D, Zuppi C, Giungi S, Luciani G, Torelli R, Posteraro B, Fadda G, Tazza L. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. CJASN. 2009;4:379–85.PubMedPubMedCentral
103.
Zurück zum Zitat Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT. Effect of an increased intraperitoneal pressure on fluid and solute transport during CAPD. Kidney Int. 1993;44:1078–85.PubMed Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT. Effect of an increased intraperitoneal pressure on fluid and solute transport during CAPD. Kidney Int. 1993;44:1078–85.PubMed
104.
Zurück zum Zitat Ribitsch W, Schneditz D, Franssen CFM, Schilcher G, Stadlbauer V, Horina JH, Rosenkranz AR. Increased hepato-splanchnic vasoconstriction in diabetics during regular hemodialysis. PLoS ONE. 2015;10: e0145411.PubMedPubMedCentral Ribitsch W, Schneditz D, Franssen CFM, Schilcher G, Stadlbauer V, Horina JH, Rosenkranz AR. Increased hepato-splanchnic vasoconstriction in diabetics during regular hemodialysis. PLoS ONE. 2015;10: e0145411.PubMedPubMedCentral
105.
Zurück zum Zitat Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 1897;2014:25. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 1897;2014:25.
106.
Zurück zum Zitat Wu I-W, Hsu K-H, Hsu H-J, Lee C-C, Sun C-Y, Tsai C-J, Wu M-S. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrology Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2012;27:1169–75. Wu I-W, Hsu K-H, Hsu H-J, Lee C-C, Sun C-Y, Tsai C-J, Wu M-S. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrology Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2012;27:1169–75.
107.
Zurück zum Zitat Wu I-W, Hsu K-H, Lee C-C, Sun C-Y, Hsu H-J, Tsai C-J, Tzen C-Y, Wang Y-C, Lin C-Y, Wu M-S. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology Dialysis Transpl Off Publ Eur Dialysis and Transpl Assoc Eur Renal Assoc. 2011;26:938–47. Wu I-W, Hsu K-H, Lee C-C, Sun C-Y, Hsu H-J, Tsai C-J, Tzen C-Y, Wang Y-C, Lin C-Y, Wu M-S. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology Dialysis Transpl Off Publ Eur Dialysis and Transpl Assoc Eur Renal Assoc. 2011;26:938–47.
108.
Zurück zum Zitat Parthasarathy G, Chen J, Chen X, Chia N, O’Connor HM, Wolf PG, Gaskins HR. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150:367-379.e361.PubMed Parthasarathy G, Chen J, Chen X, Chia N, O’Connor HM, Wolf PG, Gaskins HR. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150:367-379.e361.PubMed
109.
Zurück zum Zitat Quigley EMM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol. 2011;25:119–26.PubMed Quigley EMM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol. 2011;25:119–26.PubMed
110.
Zurück zum Zitat Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick ME, Emery SM, Sandine WE, Ayres JW. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab. 1996;22:92–6.PubMed Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick ME, Emery SM, Sandine WE, Ayres JW. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab. 1996;22:92–6.PubMed
111.
Zurück zum Zitat Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74:349–55.PubMed Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74:349–55.PubMed
112.
Zurück zum Zitat Wu I-W, Gao S-S, Chou H-C, Yang H-Y, Chang L-C, Kuo Y-L, Dinh MCV, Chung W-H, Yang C-W, Lai H-C, et al. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease. Theranostics. 2020;10:5398–411.PubMedPubMedCentral Wu I-W, Gao S-S, Chou H-C, Yang H-Y, Chang L-C, Kuo Y-L, Dinh MCV, Chung W-H, Yang C-W, Lai H-C, et al. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease. Theranostics. 2020;10:5398–411.PubMedPubMedCentral
113.
Zurück zum Zitat Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L, Lu H, Ding S, Ren H, Liu C, et al. Alterations of the human gut microbiome in chronic kidney disease. Adv Sci. 2020;7:2001936. Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L, Lu H, Ding S, Ren H, Liu C, et al. Alterations of the human gut microbiome in chronic kidney disease. Adv Sci. 2020;7:2001936.
114.
Zurück zum Zitat Païssé S, Valle C, Servant F, Courtney M, Burcelin R, Amar J, Lelouvier B. Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion. 2016;56:1138–47.PubMed Païssé S, Valle C, Servant F, Courtney M, Burcelin R, Amar J, Lelouvier B. Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion. 2016;56:1138–47.PubMed
115.
Zurück zum Zitat Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS, Fasano A. Blood microbiome profile in CKD : a pilot study. CJASN. 2019;14:692–701.PubMedPubMedCentral Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS, Fasano A. Blood microbiome profile in CKD : a pilot study. CJASN. 2019;14:692–701.PubMedPubMedCentral
116.
Zurück zum Zitat Merino-Ribas A, Araujo R, Pereira L, Campos J, Barreiros L, Segundo MA, Silva N, Costa CFFA, Quelhas-Santos J, Trindade F, et al. Vascular calcification and the gut and blood microbiome in chronic kidney disease patients on peritoneal dialysis: a pilot study. Biomolecules. 2022;12:867.PubMedPubMedCentral Merino-Ribas A, Araujo R, Pereira L, Campos J, Barreiros L, Segundo MA, Silva N, Costa CFFA, Quelhas-Santos J, Trindade F, et al. Vascular calcification and the gut and blood microbiome in chronic kidney disease patients on peritoneal dialysis: a pilot study. Biomolecules. 2022;12:867.PubMedPubMedCentral
117.
Zurück zum Zitat Sciarra F, Franceschini E, Campolo F, Venneri MA. The diagnostic potential of the human blood microbiome: are we dreaming or awake? Int J Mol Sci. 2023;24:10422.PubMedPubMedCentral Sciarra F, Franceschini E, Campolo F, Venneri MA. The diagnostic potential of the human blood microbiome: are we dreaming or awake? Int J Mol Sci. 2023;24:10422.PubMedPubMedCentral
118.
Zurück zum Zitat Lelouvier B, Servant F, Païssé S, Brunet A-C, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology. 2016;64:2015–27.PubMed Lelouvier B, Servant F, Païssé S, Brunet A-C, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology. 2016;64:2015–27.PubMed
119.
Zurück zum Zitat Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, Bansal VK, Brubaker L, Flanigan R, Koval J, et al. Diversity of the midstream urine microbiome in adults with chronic kidney disease. Int Urol Nephrol. 2018;50:1123–30.PubMedPubMedCentral Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, Bansal VK, Brubaker L, Flanigan R, Koval J, et al. Diversity of the midstream urine microbiome in adults with chronic kidney disease. Int Urol Nephrol. 2018;50:1123–30.PubMedPubMedCentral
120.
Zurück zum Zitat Matsushita K, Ballew SH, Wang AYM, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(696):707. Matsushita K, Ballew SH, Wang AYM, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(696):707.
121.
Zurück zum Zitat Braam B, Joles JA, DanishwarGaillard AHCA. Cardiorenal syndrome—current understanding and future perspectives. Nat Rev Nephrol. 2014;10:48–55.PubMed Braam B, Joles JA, DanishwarGaillard AHCA. Cardiorenal syndrome—current understanding and future perspectives. Nat Rev Nephrol. 2014;10:48–55.PubMed
122.
Zurück zum Zitat Bennett BJ, de Aguiar TQ, Vallim ZW, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ. Trimethylamine-N-Oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(49):60. Bennett BJ, de Aguiar TQ, Vallim ZW, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ. Trimethylamine-N-Oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(49):60.
123.
Zurück zum Zitat Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, Lusis AJ, Shih DM. Trimethylamine N-Oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5:e002767.PubMedPubMedCentral Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, Lusis AJ, Shih DM. Trimethylamine N-Oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5:e002767.PubMedPubMedCentral
124.
Zurück zum Zitat Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V, Badger JH, Vats R, Sundd P, Tang H-Y, et al. an interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity. 2018;49:943-957.e949.PubMedPubMedCentral Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V, Badger JH, Vats R, Sundd P, Tang H-Y, et al. an interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity. 2018;49:943-957.e949.PubMedPubMedCentral
125.
Zurück zum Zitat Lok ZSY, Lyle AN. Osteopontin in vascular disease. Arterioscler Thromb Vasc Biol. 2019;39:613–22.PubMed Lok ZSY, Lyle AN. Osteopontin in vascular disease. Arterioscler Thromb Vasc Biol. 2019;39:613–22.PubMed
126.
Zurück zum Zitat Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int. 2013;84:733–44.PubMed Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int. 2013;84:733–44.PubMed
127.
Zurück zum Zitat Campillo S, Bohorquez L, Gutiérrez-Calabrés E, García-Ayuso D, Miguel V, Griera M, Calle Y, de Frutos S, Rodríguez-Puyol M, Rodríguez-Puyol D, Calleros L. Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation. Exp Mol Med. 2022;54:226–38.PubMedPubMedCentral Campillo S, Bohorquez L, Gutiérrez-Calabrés E, García-Ayuso D, Miguel V, Griera M, Calle Y, de Frutos S, Rodríguez-Puyol M, Rodríguez-Puyol D, Calleros L. Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation. Exp Mol Med. 2022;54:226–38.PubMedPubMedCentral
128.
Zurück zum Zitat Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol. 1974;27:961–79.PubMedPubMedCentral Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol. 1974;27:961–79.PubMedPubMedCentral
129.
Zurück zum Zitat Dave M, Higgins PD, Middha S. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res J Lab Clin Med. 2012;160:246–57. Dave M, Higgins PD, Middha S. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res J Lab Clin Med. 2012;160:246–57.
130.
Zurück zum Zitat Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B, Yin J, Gao N, Shen W, Schnabl B. An Introduction to next generation sequencing bioinformatic analysis in gut microbiome studies. Biomolecules. 2021;11:530.PubMedPubMedCentral Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B, Yin J, Gao N, Shen W, Schnabl B. An Introduction to next generation sequencing bioinformatic analysis in gut microbiome studies. Biomolecules. 2021;11:530.PubMedPubMedCentral
131.
Zurück zum Zitat Luo D, Zhao W, Lin Z, Wu J, Lin H, Li Y, Song J, Zhang J. The effects of hemodialysis and peritoneal dialysis on the gut microbiota of end-stage renal disease patients, and the relationship between gut microbiota and patient prognoses. Front Cell Infect Microbiol. 2021;11: 579386.PubMedPubMedCentral Luo D, Zhao W, Lin Z, Wu J, Lin H, Li Y, Song J, Zhang J. The effects of hemodialysis and peritoneal dialysis on the gut microbiota of end-stage renal disease patients, and the relationship between gut microbiota and patient prognoses. Front Cell Infect Microbiol. 2021;11: 579386.PubMedPubMedCentral
132.
Zurück zum Zitat Sato N, Kakuta M, Hasegawa T, Yamaguchi R, Uchino E, Murashita K, Nakaji S, Imoto S, Yanagita M. Metagenomic profiling of gut microbiome in early chronic kidney disease. Nephrology Dialysis Trans Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc. 2021;36:1675–84. Sato N, Kakuta M, Hasegawa T, Yamaguchi R, Uchino E, Murashita K, Nakaji S, Imoto S, Yanagita M. Metagenomic profiling of gut microbiome in early chronic kidney disease. Nephrology Dialysis Trans Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc. 2021;36:1675–84.
133.
Zurück zum Zitat Wang X, Yang S, Li S, Zhao L, Hao Y, Qin J, Zhang L, Zhang C, Bian W, Zuo L, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020;69:2131–42.PubMed Wang X, Yang S, Li S, Zhao L, Hao Y, Qin J, Zhang L, Zhang C, Bian W, Zuo L, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020;69:2131–42.PubMed
134.
Zurück zum Zitat Opdebeeck B, Maudsley S, Azmi A, Maré A, Leger DW, Meijers DB, Verhulst A, Evenepoel P, D’Haese PC, Neven E. Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with glucose intolerance. J Am Soc Nephrol. 2019;30:751.PubMedPubMedCentral Opdebeeck B, Maudsley S, Azmi A, Maré A, Leger DW, Meijers DB, Verhulst A, Evenepoel P, D’Haese PC, Neven E. Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with glucose intolerance. J Am Soc Nephrol. 2019;30:751.PubMedPubMedCentral
135.
Zurück zum Zitat Karaduta O, Glazko G, Dvanajscak Z, Arthur J, Mackintosh S, Orr L, Rahmatallah Y, Yeruva L, Tackett A, Zybailov B. Resistant starch slows the progression of CKD in the 5/6 nephrectomy mouse model. Physiol Rep. 2020;8:e14610.PubMedPubMedCentral Karaduta O, Glazko G, Dvanajscak Z, Arthur J, Mackintosh S, Orr L, Rahmatallah Y, Yeruva L, Tackett A, Zybailov B. Resistant starch slows the progression of CKD in the 5/6 nephrectomy mouse model. Physiol Rep. 2020;8:e14610.PubMedPubMedCentral
136.
Zurück zum Zitat Lobel L, Cao YG, Fenn K, Glickman JN, Garrett WS. Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function. Science. 2020;369(1518):1524. Lobel L, Cao YG, Fenn K, Glickman JN, Garrett WS. Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function. Science. 2020;369(1518):1524.
137.
Zurück zum Zitat Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJH. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82(465):473. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJH. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82(465):473.
138.
Zurück zum Zitat Dasari S, Alexander MP, Vrana JA, Theis JD, Mills JR, Negron V, Sethi S, Dispenzieri A, Highsmith WEJ, Nasr Kurtin SH, DnaJ PJ. Heat shock protein family B member 9 is a novel biomarker for fibrillary. GN J Am Soc Nephrol. 2018;29:1–51. Dasari S, Alexander MP, Vrana JA, Theis JD, Mills JR, Negron V, Sethi S, Dispenzieri A, Highsmith WEJ, Nasr Kurtin SH, DnaJ PJ. Heat shock protein family B member 9 is a novel biomarker for fibrillary. GN J Am Soc Nephrol. 2018;29:1–51.
139.
Zurück zum Zitat Ma L, Palmer ND, Choi YA, Murea M, Snipes JA, Parks JS, Langefeld CD, Freedman I. BI APOL1 risk variants impair multiple mitochondrial pathways in a metabolomics analysis. Kidney. 2020;360(1):1353. Ma L, Palmer ND, Choi YA, Murea M, Snipes JA, Parks JS, Langefeld CD, Freedman I. BI APOL1 risk variants impair multiple mitochondrial pathways in a metabolomics analysis. Kidney. 2020;360(1):1353.
140.
Zurück zum Zitat Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun WA. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br J Nutr. 2008;100(530):541. Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun WA. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br J Nutr. 2008;100(530):541.
141.
Zurück zum Zitat Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006;130:731–46.PubMed Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006;130:731–46.PubMed
142.
Zurück zum Zitat Zhang R, Li Z, Gu X, Zhao J, Guo T, Kong J. Probiotic Bacillus subtilis LF11 protects intestinal epithelium against salmonella infection. Front Cell Infect Microbiol. 2022;12:837886.PubMedPubMedCentral Zhang R, Li Z, Gu X, Zhao J, Guo T, Kong J. Probiotic Bacillus subtilis LF11 protects intestinal epithelium against salmonella infection. Front Cell Infect Microbiol. 2022;12:837886.PubMedPubMedCentral
143.
Zurück zum Zitat Cotter PD, Hill C. Ross RP Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005;3:777–88.PubMed Cotter PD, Hill C. Ross RP Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005;3:777–88.PubMed
144.
Zurück zum Zitat Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003;41:S142–5.PubMed Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003;41:S142–5.PubMed
145.
Zurück zum Zitat Zhu H, Cao C, Wu Z, Zhang H, Sun Z, Wang M, Xu H, Zhao Z, Wang Y, Pei G, et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab. 2021;33:1926-1942.e1928.PubMed Zhu H, Cao C, Wu Z, Zhang H, Sun Z, Wang M, Xu H, Zhao Z, Wang Y, Pei G, et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab. 2021;33:1926-1942.e1928.PubMed
146.
Zurück zum Zitat Quigley EMM Prebiotics and Probiotics in Digestive Health. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterol Assoc. 2019;17:333–44. Quigley EMM Prebiotics and Probiotics in Digestive Health. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterol Assoc. 2019;17:333–44.
147.
Zurück zum Zitat Sarao LK, Arora M. Probiotics, prebiotics, and microencapsulation: a review. Crit Rev Food Sci Nutr. 2017;57:344–71.PubMed Sarao LK, Arora M. Probiotics, prebiotics, and microencapsulation: a review. Crit Rev Food Sci Nutr. 2017;57:344–71.PubMed
148.
Zurück zum Zitat Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016;5: e73. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016;5: e73.
149.
Zurück zum Zitat Akbari P, Fink-Gremmels J, Willems RHAM, Difilippo E, Schols HA, Schoterman MHC, Garssen J, Braber S. Characterizing microbiota-independent effects of oligosaccharides on intestinal epithelial cells: insight into the role of structure and size. Eur J Nutr. 2017;56:1919–30.PubMed Akbari P, Fink-Gremmels J, Willems RHAM, Difilippo E, Schols HA, Schoterman MHC, Garssen J, Braber S. Characterizing microbiota-independent effects of oligosaccharides on intestinal epithelial cells: insight into the role of structure and size. Eur J Nutr. 2017;56:1919–30.PubMed
150.
Zurück zum Zitat Meijers BKI, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. p -Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transpl. 2010;25:219–24. Meijers BKI, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. p -Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transpl. 2010;25:219–24.
151.
Zurück zum Zitat Rossi M, Johnson DW, Xu H, Carrero JJ, Pascoe E, French C, Campbell KL. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutr Metab Cardiovasc Dis. 2015;25(860):865. Rossi M, Johnson DW, Xu H, Carrero JJ, Pascoe E, French C, Campbell KL. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutr Metab Cardiovasc Dis. 2015;25(860):865.
152.
Zurück zum Zitat Kelly JT, Palmer SC, Wai SN, Ruospo M, Carrero J-J, Campbell KL, Strippoli GFM. Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 2017;12:272–9.PubMed Kelly JT, Palmer SC, Wai SN, Ruospo M, Carrero J-J, Campbell KL, Strippoli GFM. Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 2017;12:272–9.PubMed
153.
Zurück zum Zitat Marques FZ, Nelson E, Chu P-Y, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation. 2017;135:964–77.PubMed Marques FZ, Nelson E, Chu P-Y, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation. 2017;135:964–77.PubMed
154.
Zurück zum Zitat Zmora N, Suez J, Elinav E. You are what you eat diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16:35–56.PubMed Zmora N, Suez J, Elinav E. You are what you eat diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16:35–56.PubMed
155.
Zurück zum Zitat Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, Kitazawa S, Fukagawa M. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2009;24(2089):2095. Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, Kitazawa S, Fukagawa M. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dialysis Transpl Off Publ Eur Dialysis Transpl Assoc Eur Renal Assoc. 2009;24(2089):2095.
156.
Zurück zum Zitat Huang Y, Zhou J, Wang S, Xiong J, Chen Y, Liu Y, Xiao T, Li Y, He T, Li Y, et al. Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment. Theranostics. 2020;10:7384–400.PubMedPubMedCentral Huang Y, Zhou J, Wang S, Xiong J, Chen Y, Liu Y, Xiao T, Li Y, He T, Li Y, et al. Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment. Theranostics. 2020;10:7384–400.PubMedPubMedCentral
157.
Zurück zum Zitat Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9:1021.PubMedPubMedCentral Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9:1021.PubMedPubMedCentral
158.
Zurück zum Zitat Saulnier DMA, Spinler JK, Gibson GR, Versalovic J. Mechanisms of probiosis and prebiosis considerations for enhanced functional foods. Curr Opin Biotechnol. 2009;20(135):141. Saulnier DMA, Spinler JK, Gibson GR, Versalovic J. Mechanisms of probiosis and prebiosis considerations for enhanced functional foods. Curr Opin Biotechnol. 2009;20(135):141.
159.
Zurück zum Zitat Guida B, Germanò R, Trio R, Russo D, Memoli B, Grumetto L, Barbato F, Cataldi M. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis. 2014;24:1043–9.PubMed Guida B, Germanò R, Trio R, Russo D, Memoli B, Grumetto L, Barbato F, Cataldi M. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis. 2014;24:1043–9.PubMed
160.
Zurück zum Zitat Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto C-C, McWhinney BC, Ungerer JPJ, Campbell KL. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol. 2016;11:223–31.PubMedPubMedCentral Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto C-C, McWhinney BC, Ungerer JPJ, Campbell KL. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol. 2016;11:223–31.PubMedPubMedCentral
161.
Zurück zum Zitat Yang C-Y, Chen T-W, Lu W-L, Liang S-S, Huang H-D, Tseng C-P, Tarng D-C. Synbiotics alleviate the gut indole load and dysbiosis in chronic kidney disease. Cells. 2021;10:114.PubMedPubMedCentral Yang C-Y, Chen T-W, Lu W-L, Liang S-S, Huang H-D, Tseng C-P, Tarng D-C. Synbiotics alleviate the gut indole load and dysbiosis in chronic kidney disease. Cells. 2021;10:114.PubMedPubMedCentral
162.
Zurück zum Zitat Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D. Curhan GC The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med. 2003;138:460–7.PubMed Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D. Curhan GC The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med. 2003;138:460–7.PubMed
163.
Zurück zum Zitat Ko G-J, Rhee CM, Kalantar-Zadeh K, Joshi S. The effects of high-protein diets on kidney health and longevity. J Am Soc Nephrol. 2020;31:1667–79.PubMedPubMedCentral Ko G-J, Rhee CM, Kalantar-Zadeh K, Joshi S. The effects of high-protein diets on kidney health and longevity. J Am Soc Nephrol. 2020;31:1667–79.PubMedPubMedCentral
164.
Zurück zum Zitat Tovar-Palacio C, Tovar AR, Torres N, Cruz C, Hernández-Pando R, Salas-Garrido G, Pedraza-Chaverri J, Correa-Rotter R. Proinflammatory gene expression and renal lipogenesis are modulated by dietary protein content in obese Zucker fa/fa rats. Am J Physiol-Renal Physiol. 2011;300:F263–71.PubMed Tovar-Palacio C, Tovar AR, Torres N, Cruz C, Hernández-Pando R, Salas-Garrido G, Pedraza-Chaverri J, Correa-Rotter R. Proinflammatory gene expression and renal lipogenesis are modulated by dietary protein content in obese Zucker fa/fa rats. Am J Physiol-Renal Physiol. 2011;300:F263–71.PubMed
165.
Zurück zum Zitat Lew Q-LJ, Jafar TH, Koh HWL, Jin A, Chow KY, Yuan J-M, Red KWP. Meat intake and risk of ESRD. J Am Soc Nephrol. 2017;28:304–12.PubMed Lew Q-LJ, Jafar TH, Koh HWL, Jin A, Chow KY, Yuan J-M, Red KWP. Meat intake and risk of ESRD. J Am Soc Nephrol. 2017;28:304–12.PubMed
166.
Zurück zum Zitat Kamper A-L, Strandgaard S. Long-term effects of high-protein diets on renal function. Annu Rev Nutr. 2017;37:347–69.PubMed Kamper A-L, Strandgaard S. Long-term effects of high-protein diets on renal function. Annu Rev Nutr. 2017;37:347–69.PubMed
167.
Zurück zum Zitat Hostetter TH, Meyer TW, Rennke HG, Brenner Noddin BM, Wttao JA, Sandstrom DJ. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986;30:509–17.PubMed Hostetter TH, Meyer TW, Rennke HG, Brenner Noddin BM, Wttao JA, Sandstrom DJ. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986;30:509–17.PubMed
168.
Zurück zum Zitat Sakaguchi Y, Kaimori J-Y. Isaka Y plant-dominant low protein diet: a potential alternative dietary practice for patients with chronic kidney disease. Nutrients. 2023;15:1002.PubMedPubMedCentral Sakaguchi Y, Kaimori J-Y. Isaka Y plant-dominant low protein diet: a potential alternative dietary practice for patients with chronic kidney disease. Nutrients. 2023;15:1002.PubMedPubMedCentral
169.
Zurück zum Zitat Microbiome SJL, Engineering. Nature. 2015;518:S10–S10. Microbiome SJL, Engineering. Nature. 2015;518:S10–S10.
170.
Zurück zum Zitat Devlin AS, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T, Pollard KS, Sonnenburg JL. Fischbach MA modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe. 2016;20:709–15.PubMedPubMedCentral Devlin AS, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T, Pollard KS, Sonnenburg JL. Fischbach MA modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe. 2016;20:709–15.PubMedPubMedCentral
171.
Zurück zum Zitat Prakash S, Chang TMS. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Med. 1996;2:883–7.PubMed Prakash S, Chang TMS. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Med. 1996;2:883–7.PubMed
172.
Zurück zum Zitat Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–5.PubMed Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–5.PubMed
173.
Zurück zum Zitat Ting S-Y, Martínez-García E, Huang S, Bertolli SK, Kelly KA, Cutler KJ, Su ED, Zhi H, Tang Q, Radey MC, et al. Targeted depletion of bacteria from mixed populations by programmable adhesion with antagonistic competitor cells. Cell Host Microbe. 2020;28:313-321.e316.PubMedPubMedCentral Ting S-Y, Martínez-García E, Huang S, Bertolli SK, Kelly KA, Cutler KJ, Su ED, Zhi H, Tang Q, Radey MC, et al. Targeted depletion of bacteria from mixed populations by programmable adhesion with antagonistic competitor cells. Cell Host Microbe. 2020;28:313-321.e316.PubMedPubMedCentral
174.
Zurück zum Zitat van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EdJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368(407):415. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EdJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368(407):415.
175.
Zurück zum Zitat FUAD Others. Guidance for industry biologics evaluation and research, us food and drug administration. Berlin: Silver Spring; 2013. FUAD Others. Guidance for industry biologics evaluation and research, us food and drug administration. Berlin: Silver Spring; 2013.
178.
Zurück zum Zitat Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H. Systematic review: adverse events of fecal microbiota transplantation. PLoS ONE. 2016;11: e0161174.PubMedPubMedCentral Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H. Systematic review: adverse events of fecal microbiota transplantation. PLoS ONE. 2016;11: e0161174.PubMedPubMedCentral
Metadaten
Titel
The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies
verfasst von
Zijing Tang
Shiyan Yu
Yu Pan
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2023
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-023-04455-2

Weitere Artikel der Ausgabe 1/2023

Journal of Translational Medicine 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.